Skip to content
OTC Biotech
  • Home
  • Contact
  • About
    • Privacy Policy

Allen Williams

Dr. Richard Gallo, Co-Founder of MatriSys Bioscience, Honored by Leading Dermatology and Allergy Organizations

March 21, 2023 by Allen Williams

Matrisys Bioscience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic dermatologic indications, is proud to announce that its scientific … Read more

IGC Transforms Into IGC Pharma, Inc. – Get Ready for a New Beginning!

March 21, 2023 by Allen Williams

IGC Pharma, Inc. (formerly Globalization Capital, Inc.) is launching a rebranding initiative to better represent its strategic focus and vision for the future. On March … Read more

Record-Setting Payouts for Moderna, Pfizer CEOs: A Growing Trend?

March 21, 2023 by Allen Williams

The COVID-19 pandemic has proved to be a massive boon for many biotech companies, resulting in large profits and handsome pay increases for their chief … Read more

Takeda’s $4 Billion Miracle Drug for Psoriasis Passes Mid-Stage Clinical Trial

March 21, 2023 by Allen Williams

Takeda is on the brink of a major breakthrough with its experimental drug for plaque psoriasis, TAK-279. Following a successful Phase IIb study that met … Read more

Karuna’s KarXT Shines in Third Schizophrenia Study – Promising Results!

March 21, 2023 by Allen Williams

Karuna Therapeutics has achieved a major milestone in its mission to bring a revolutionary new treatment for schizophrenia to the public: the results of its … Read more

Novartis and Biogen Terminate Gene Regulation Collaboration with Sangamo

March 21, 2023 by Allen Williams

Friday was a devastating day for Sangamo Therapeutics, as two of their most powerful partners, Novartis and Biogen, announced that they were ending their collaborations … Read more

Dynanet Wins Prestigious CMS ACME BPA Award

March 21, 2023 by Allen Williams

The Centers for Medicare & Medicaid Services (CMS) has awarded Dynanet a Prime contract as part of the $1,000,000,000 Agile Collaboration and Modernization Endeavors (ACME) … Read more

FDA Grants Prestige Biopharma Fast Track Status for Revolutionary Pancreatic Cancer Treatment!

March 21, 2023 by Allen Williams

Prestige Biopharma has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for PBP1510 (International Non-proprietary name: Ulenistamab), a revolutionary potential … Read more

CTI BioPharma Grants Inducements to Bolster Nasdaq Listing – March 21, 2023

March 21, 2023 by Allen Williams

CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company dedicated to the development and commercialization of groundbreaking treatments for blood-related cancers, proudly announced the granting … Read more

A Rollercoaster Ride: Following Novavax Through Its Ups and Downs to Its Next Chapter

March 21, 2023 by Allen Williams

It was a story that could have come out of a fairytale book. A small American vaccine maker rose to the challenge of the pandemic … Read more

Unlocking Hope: New Data from Open Label Extension of VILTEPSO® (viltolarsen) Injection to be Presented at MDA 2023 Conference

March 20, 2023 by Allen Williams

NS Pharma is delighted to take part in the 2023 Muscular Dystrophy Association’s Clinical & Scientific Congress in Dallas, Texas! We are proud to be … Read more

Revolutionary Test Unveiled at 2023 AAD Meeting: DecisionDx®-SCC Beats Traditional Staging Systems in Predicting Metastatic Risk!

March 20, 2023 by Allen Williams

Castle Biosciences, Inc. (Nasdaq: CSTL) has recently shared new performance data from a multi-center, independent cohort that confirms the independent risk-stratification of DecisionDx®-SCC (the Company’s … Read more

Rapid Relief Seen in Chinese Patients with Atopic Dermatitis in Breakthrough Biopharma CBP-201 Pivotal Study

March 20, 2023 by Allen Williams

Connect Biopharma Holdings Limited (Nasdaq: CNTB) has announced the promising results of Stage 1 of its pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD). … Read more

California Takes Steps for Safer, More Affordable Insulin with Civica Rx Partnership

March 20, 2023 by Allen Williams

Civica Inc. is proud to announce that it will be producing insulins for the State of California’s CalRx Biosimilar Insulin Initiative. Once approved, Civica’s biosimilar … Read more

Breakthrough Study Reveals Sweat Control Patch Effectively Curbs Excessive Underarm Sweating

March 20, 2023 by Allen Williams

Candesant Biomedical, a medical device company devoted to providing non-invasive treatments for hyperhidrosis, has unveiled the results of its groundbreaking clinical trial for its revolutionary … Read more

Acelyrin, Inc. Achieves Remarkable Results: 100% Response Rate to Izokibep in 12 Weeks for Moderate-to-Severe Hidradenitis Suppurativa!

March 20, 2023 by Allen Williams

Acelyrin, Inc, a late-stage clinical biopharma company dedicated to delivering transformative medicines in immunology, has announced remarkable data from their Phase 2b/3 trial in patients … Read more

Hundreds of Workers Left Jobless as Amgen Cuts 450 Positions in 2020

March 20, 2023 by Allen Williams

Amgen announced a major restructuring plan on Friday with the aim of weathering the impacts of falling drug prices and rising inflation. As part of … Read more

The Unresolved Dispute Between Esperion and Daiichi Sankyo: Who Will Pay Up?

March 20, 2023 by Allen Williams

Daiichi Sankyo was unimpressed with the results of the Phase III CLEAR trial of Esperion Therapeutic’s cholesterol-lowering candidate Nexletol (bempedoic acid), as the results were … Read more

Takeda Oncology Plants Seeds for Future Success Despite Unstable Market

March 20, 2023 by Allen Williams

It’s been an eventful start to the year for life science companies, with numerous firms expanding their pipelines and joining forces with resource-limited organizations to … Read more

Pfizer and Astellas Aim to Broaden Access to Costly Prostate Cancer Treatment

March 20, 2023 by Allen Williams

Pfizer and Astellas are celebrating the positive topline Phase III results for Xtandi (enzalutamide) announced on Thursday, raising hopes of adding another indication to the … Read more

Vanda Pharmaceuticals Welcomes Industry Leader Dr. Tage Honoré to its Board of Directors

March 17, 2023 by Allen Williams

Vanda Pharmaceuticals, Inc. (VNDA: Nasdaq) is pleased to announce the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors, effective March 15, 2023. … Read more

Tiziana Life Sciences: A Story of Success Highlighted in Forbes

March 17, 2023 by Allen Williams

Tiziana Life Sciences Plc (Nasdaq: TLSA), a pioneering biotechnology company developing cutting-edge immunomodulation therapies, has recently been highlighted in a FORBES article. The article focuses … Read more

Unlocking the Potential of Cancer Treatment: Predictive Oncology and Cancer Research Horizons Join Forces!

March 17, 2023 by Allen Williams

Predictive Oncology Inc. (NASDAQ: POAI) and Cancer Research Horizon, the innovation engine of Cancer Research UK (CRUK), have joined forces to develop next-generation oncology drugs … Read more

Unleashing a Biosimilar Revolution: Bioepis Unveils SB17 Study Results at 2023 AAD Meeting

March 17, 2023 by Allen Williams

SB17, the proposed biosimilar to Stelara1 (ustekinumab), has proved its mettle in a Phase 1 clinical study with healthy volunteers. It demonstrated pharmacokinetic (PK) bioequivalence … Read more

5-Year Survival Rate for Glioblastoma Patients Soars to 67% Thanks to CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial

March 17, 2023 by Allen Williams

CANbridge Pharmaceuticals, Inc. (1228.HK) is delighted to announce that long-term follow up data from the Phase 1/2 study of CAN008 (asunercept) plus temozolomide/radiotherapy (TMZ/RT) in … Read more

Zevra Therapeutics Joins Forces with RARE-X and Sleep Consortium to Launch Cutting-Edge Sleep Data Initiative.

March 17, 2023 by Allen Williams

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (formerly KemPharm, Inc.), a rare disease therapeutics company, has joined forces with the Sleep Data Initiative, led by RARE-X and … Read more

Record-Breaking Year for Kelyniam Global: $3 Million in Sales in 2022!

March 17, 2023 by Allen Williams

Kelyniam Global (OTC: KLYG), a leader in the innovative field of custom cranial implants, is proud to report outstanding results for its year ended December … Read more

Tiziana Life Sciences Chairman and Acting CEO Invest in Company’s Future with Share Purchase

March 17, 2023 by Allen Williams

Tiziana Life Sciences Plc. (Nasdaq: TLSA), a biotechnology company developing innovative immunomodulation therapies through cutting-edge drug delivery methods, has today announced that its Chairman and … Read more

Discover the Power of Aesthetics: Advanced Medaesthetic Partners Invests in Destination Aesthetics

March 17, 2023 by Allen Williams

AMP, a leader in the medical aesthetic services industry, is proud to announce its strategic partnership with Destination Aesthetics™ (DA), the top Medical Spa in … Read more

FDA U-Turn: Adcomm Meeting Scheduled for Sarepta’s Revolutionary DMD Gene Therapy

March 17, 2023 by Allen Williams

The U.S. Food and Drug Administration (FDA) has decided to move forward with a meeting of its advisory committee regarding Sarepta’s investigational gene therapy for … Read more

Discover the Power of NeoGenomics’ RaDaR(R) Molecular Residual Disease Test!

March 16, 2023 by Allen Williams

NeoGenomics, Inc. (NASDAQ:NEO) is thrilled to announce the commercial launch of its highly anticipated liquid biopsy test, RaDaR®, for molecular/minimal residual disease (MRD). RaDaR is … Read more

Saol Therapeutics Pioneers Breakthrough Treatment for Glioblastoma and Rare Pediatric Cancers with Dichloroacetate (DCA; SL-1009)

March 16, 2023 by Allen Williams

Today, Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced an exciting new agreement with Medosome Biotec, LLC that will allow them to use their … Read more

Revolutionary ATH434 Treatment Now Available in the US: Alterity Therapeutics Enrolls First Patient in Multiple System Atrophy Phase 2 Clinical Trial

March 16, 2023 by Allen Williams

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is proud to announce that the first participant has been successfully dosed in their Phase 2 clinical trial of … Read more

Purple Biotech Unveils Promising Biomarker Results from CM24 Clinical Trial

March 16, 2023 by Allen Williams

Purple Biotech, a clinical-stage company developing groundbreaking therapies that exploit the power of the tumor microenvironment, today released exciting results from their Phase 1 dose … Read more

Revolutionizing Hernia Treatment: Clinical Research Unveils the Safety and Performance of Reinforced Biologic!

March 16, 2023 by Allen Williams

TELA Bio, Inc. (NASDAQ: TELA) is proud to share the results of six groundbreaking studies published in 2022, which demonstrate the efficacy of their revolutionary … Read more

Invitae Welcomes Experienced Oncologist Dr. W. Michael Korn as Chief Medical Officer

March 16, 2023 by Allen Williams

Invitae (NYSE: NVTA), a leading medical genetics company, is proud to welcome W. Michael Korn, M.D., as its new chief medical officer for oncology. Dr. … Read more

First Patient Dosed in Trial of Revolutionary Cancer-Fighting Drug PYX-201!

March 16, 2023 by Allen Williams

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage research and development company focused on developing cancer treatments of the future, has announced the successful dosing of … Read more

Arbutus Ushers in a New Era of RNA Destabilization with Successful Phase 1 Clinical Trial of Oral Drug AB-161

March 16, 2023 by Allen Williams

Arbutus Biopharma Corporation (Nasdaq: ABUS) has taken a major step forward in its mission to provide a potential functional cure for hepatitis B virus (HBV) … Read more

MediWound Welcomes Hani Luxenburg as New CFO to Lead Financial Team

March 16, 2023 by Allen Williams

MediWound Ltd. (Nasdaq: MDWD), a leading biopharmaceutical company that specializes in developing advanced biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the … Read more

Revolutionizing MDD Treatment: Tonix Pharmaceuticals Launches UPLIFT Study of TNX-601 ER for Major Depressive Disorder

March 16, 2023 by Allen Williams

Tonix Pharmaceuticals, Inc. (Nasdaq: TNXP) has announced the enrollment of the first participant in the Phase 2 ‘UPLIFT’ clinical trial for TNX-601 ER1 (tianeptine hemioxalate … Read more

Cognition Therapeutics Aims to Combat Dry AMD with Oral CT1812 Treatment in Geographic Atrophy Patients

March 15, 2023 by Allen Williams

Cognition Therapeutics Inc. (NASDAQ: CGTX) has received a green light from the U.S. Food and Drug Administration (FDA) to move forward with their Investigational New … Read more

New Employee Opportunities Await: Scholar Rock Grants Inducements Under Nasdaq Listing Rule 5635(c)(4)

March 15, 2023 by Allen Williams

Scholar Rock (NASDAQ: SRRK) announced that they have granted a newly hired employee incentive equity awards covering an aggregate of 26,250 shares of their common … Read more

Revolutionary Treatment: First Patients Receive RCT1100 in Clinical Trial to Combat Primary Ciliary Dyskinesia

March 15, 2023 by Allen Williams

ReCode Therapeutics, a private, clinical-stage genetic medicines company, is leading the way with the next wave of mRNA and gene correction therapeutics. Today, the first … Read more

Resolve Biosciences Welcomes John Stark as New CEO to Lead the Company Forward

March 15, 2023 by Allen Williams

Resolve Biosciences, a leader in Molecular Cartography™ technology, has announced the appointment of John Stark as its new Chief Executive Officer. With this change, Jason … Read more

FDA Approves Edesa Biotech’s Proposed Primary Endpoint for Phase 3 ARDS Drug Study!

March 15, 2023 by Allen Williams

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company that focuses on inflammatory and immune-related diseases, has announced that after successful negotiations with the U.S. Food … Read more

ImmunoPrecise Subsidiary Talem Therapeutics Partners with Libera Bio to Uncover Novel Therapies with AI-Powered Antibody Discovery

March 15, 2023 by Allen Williams

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) and its independently-operating subsidiary Talem Therapeutics LLC have teamed up with Libera Bio S.L. to tackle the challenge of “undruggable” … Read more

Perspectum Makes Big Move with $19 Million Series C Funding Led by Oppenheimer & Co. Inc.

March 15, 2023 by Allen Williams

Perspectum Diagnostics, a pioneer in precision health, is revolutionizing medical imaging with its innovative tools to diagnose metabolic diseases and cancer. The company has just … Read more

Nanite Inc. Unlocks Potential for Revolutionary Lung Therapy with $2M Investment from CF Foundation

March 15, 2023 by Allen Williams

Nanite Inc. is thrilled to announce an exciting investment from the Cystic Fibrosis Foundation – a whopping $2 million! This funding will be used to … Read more

Two Pharmaceutical Giants Join Forces to Lower Insulin Prices: Novo Nordisk and Eli Lilly Take Action to Create Affordable Treatments for Diabetes Patients

March 15, 2023 by Allen Williams

As the world begins to move past the devastating effects of the pandemic, drug affordability has become a major issue for many patients in the … Read more

Veru Pushes Ahead with Final-Stage COVID Trial Despite FDA Setback

March 15, 2023 by Allen Williams

Veru has announced its intention to press forward with the late-stage development of sabizabulin, despite the FDA’s rejection of its Emergency Use Authorization (EUA) application … Read more

RAPT Therapeutics Ends Year With $249.1 Million in Cash Reserves

March 14, 2023 by Allen Williams

RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company that is dedicated to developing innovative oral small molecule therapies to address unmet needs in inflammatory diseases and … Read more

XORTX Gearing Up for May 1st Milestone: FDA Meeting on the Horizon!

March 14, 2023 by Allen Williams

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has … Read more

A Promising Step Forward: Puma Biotech’s Phase II Clinical Trial of Alisertib Published in JAMA Oncology

March 14, 2023 by Allen Williams

Puma Biotechnology, Inc. (NASDAQ: PBYI) has just released the results of an exciting clinical trial investigating the potential of alisertib to treat endocrine-resistant advanced breast … Read more

Oragenics Achieves Revolutionary Breakthrough in Battling MRSA and VRE!

March 14, 2023 by Allen Williams

Oragenics Inc. (NYSE American: OGEN) is thrilled to announce the successful results of its lantibiotics platform in combating multiple resistant pathogens. This novel class of … Read more

Ultragenyx Boosts Executive Team with Dr. Eric Crombez as Chief Medical Officer and Executive Vice President

March 14, 2023 by Allen Williams

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has appointed Eric Crombez, M.D., as its new chief medical officer and executive vice president, effective May 1, 2023. Dr. … Read more

Exploring New Hope for Hematologic Malignancies: TSC-100 and TSC-101 Tested in First Patient of Phase 1 Clinical Trial

March 14, 2023 by Allen Williams

TScan Therapeutics, Inc. (Nasdaq: TCRX) is thrilled to announce that the first patient has been successfully dosed as part of its Phase 1 umbrella trial … Read more

Unlocking the Potential of Keytruda: Exploring the Possibilities of Merck’s Clinical Trials

March 14, 2023 by Allen Williams

Keytruda (pembrolizumab) is a revolutionary drug that has revolutionized cancer therapy, earning a staggering $21 billion in 2022 alone. Its presence has been felt across … Read more

Exploring the Aftermath of SVB’s Collapse: What Lies Ahead for the Biotech Industry?

March 14, 2023 by Allen Williams

On Friday, without warning, Silicon Valley Bank (SVB) shocked the financial world with its sudden and unexpected failure. On Monday, President Biden declared that he … Read more

Novartis Makes Move to Transform Ophthalmology Market with Potential Asset Sale

March 14, 2023 by Allen Williams

Novartis is taking decisive steps to focus on its growth areas, as evidenced by its decision to sell off some of its ophthalmology portfolio assets, … Read more

Revolutionary AMPK Activator Launched to Combat Obesity in Clinics

March 14, 2023 by Allen Williams

Cambrian BioPharma is making a big move in the longevity biotech space with the launch of Amplifier Therapeutics. This clinical-stage company is focused on developing … Read more

Discovering New Potential in Adult Stem Cells: Therapeutic Solutions International Unlocks Mechanism of Action to Combat COPD

March 13, 2023 by Allen Williams

Therapeutic Solutions International (TSOI) has made a groundbreaking discovery that has the potential to revolutionize treatments for Chronic Obstructive Pulmonary Disease (COPD). By studying a … Read more

Ratio Therapeutics Welcomes Dr. Noel Monks as New Head of Biology

March 13, 2023 by Allen Williams

Ratio Therapeutics Inc., a pioneering pharmaceutical company dedicated to developing targeted radiotherapeutics for cancer treatment, is delighted to welcome Dr. Noel Monks as its new … Read more

USPTO Awards Patent to Combined Therapeutics for Revolutionary mRNA Vaccine Platform

March 13, 2023 by Allen Williams

Combined Therapeutics Inc. (CTx) has reinforced its intellectual property position in mRNA vaccine technology through the issuance of U.S. Patent 11,596,685 by the United States … Read more

Green Light for Theragnostics: $15M Series B, Discovery Unit Launch, and Ga-68 DOTATOC Supply Chain Ready!

March 13, 2023 by Allen Williams

Evergreen Theragnostics, a clinical stage contract development and manufacturing organization (CDMO) developing innovative radiopharmaceuticals for cancer therapy, has successfully completed a $15M Series B capital … Read more

Revelation Biosciences Taps Top Scientists Julia Bohannon and Antonio Hernandez to Join Advisory Board

March 13, 2023 by Allen Williams

Revelation Biosciences Inc. (NASDAQ: REVB) is thrilled to announce the addition of two esteemed scientists, Julia Bohannon, Ph.D. and Antonio Hernandez, M.D., to its scientific … Read more

Sanofi Strengthens Diabetes Leadership with $2.9B Purchase of Provention

March 13, 2023 by Allen Williams

Sanofi, one of the world’s largest pharmaceutical companies, announced Monday that it has struck a deal to acquire diabetes leader Provention Bio for an impressive … Read more

Pfizer Snatches Up Seagen in $43 Billion Winner-Take-All Bid

March 13, 2023 by Allen Williams

Hours after Sanofi and Provention Bio made headlines with a potential biopharma deal, Pfizer one-upped them with a surprise announcement – it had won the … Read more

Breaking News: Apellis and Pfizer to Revolutionize Drug Therapy with Biogen/Ionis Partnership

March 13, 2023 by Allen Williams

This week, the FDA has an exciting agenda lined up, with a target action date and an advisory committee meeting that could be a game-changer … Read more

Revolutionary Diabetes Treatments Vie for First-of-its-Kind Gene Therapy

March 13, 2023 by Allen Williams

Genome editing has been a much-debated topic in recent years, with the emergence of CRISPR technology in the spotlight. Scientists and investors alike have been … Read more

Biotechs Reeling in Wake of SVB’s Autumn Leaves

March 13, 2023 by Allen Williams

In a stunning move, the California Department of Financial Protection and Innovation (DFPI) recently shut down the prestigious Silicon Valley Bank (SVB), one of the … Read more

Revolutionizing the Surgical Experience: Sight Sciences Unveils the Ergo-Series of the OMNI® Surgical System

March 10, 2023 by Allen Williams

Sight Sciences, Inc. (Nasdaq: SGHT) is thrilled to announce the US launch of the Ergo-Series of the OMNI® Surgical System, the latest in eyecare technology. … Read more

Unlock Your Dream Job with ChatGPT: An Innovative Tool to Aid Your Job Search!

March 10, 2023 by Allen Williams

Are you ready to experience the power of AI? ChatGPT is a chatbot that uses advanced artificial intelligence to respond to questions and prompts in … Read more

AstraZeneca Scores Double Victory in Advanced Lung Cancer Trials

March 10, 2023 by Allen Williams

AstraZeneca’s groundbreaking drug Tagrisso (osimertinib) has demonstrated a remarkable boost to overall survival (OS) as an adjuvant treatment for early non-small cell lung cancer (NSCLC) … Read more

Bayer Gears Up to Ramp Up US Pharma R&D in 2023

March 10, 2023 by Allen Williams

Bayer is making a major commitment to the United States, dedicating an impressive $1 billion investment to pharmaceutical R&D in 2023. This infusion of capital … Read more

Lilly’s Latest Alzheimer’s Drug Fails to Live Up to Hope in Phase III Trial

March 10, 2023 by Allen Williams

Eli Lilly has had a tough time in its search for an Alzheimer’s disease treatment this year, as the latest data released from the Phase … Read more

Clene’s ALS Treatment Reaps Rewards with Promising Results

March 10, 2023 by Allen Williams

Clene Inc.’s gold nanocrystal therapy for ALS, although missing the initial mark, still offers hope. On Thursday, the company released encouraging results from an exploratory … Read more

QurAlis Scores Major Investment with Biomarker-Fueled Strategy

March 10, 2023 by Allen Williams

QurAlis, a biotech company pioneering a biomarker-driven approach to treating ALS, announced a successful conclusion to its oversubscribed Series B round on Thursday, raising a … Read more

China Takes a Step Forward in Cancer Treatment with First Dose of BCL2 Inhibitor ICP-248

March 10, 2023 by Allen Williams

InnoCare Pharma (HKEX: 09969; SSE: 688428), a pioneering biopharmaceutical company dedicated to the treatment of cancer and autoimmune diseases, is proud to announce that the … Read more

Allorion Therapeutics Takes Big Step Forward with $50 Million Series B Financing to Combat Oncology and Autoimmune Diseases

March 10, 2023 by Allen Williams

Allorion Therapeutics, a biotech powerhouse in precision medicine for oncology and autoimmune diseases, has just closed a remarkable $50 million Series B financing round, co-led … Read more

BIG NEWS: AusperBio Initiates Human Trials of Promising Drug for Chronic Hepatitis B

March 10, 2023 by Allen Williams

AusperBio, the joint venture of Ausper Biopharma Co. Ltd. and AusperBio Therapeutic, Inc., is proud to announce the successful completion of the first cohort dosing … Read more

ZTlido® Ready to Conquer MENA: Scilex and CH Trading Group Ink $105 Million Deal for Distribution

March 9, 2023 by Allen Williams

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is excited to announce a revolutionary territory distribution agreement for their acclaimed non-opioid pain management … Read more

Unlock the Secrets of Yield10 Bioscience’s Financial Performance – Q4 & FY 2022 Results Revealed March 14th!

March 9, 2023 by Allen Williams

Yield10 Bioscience, Inc. (Nasdaq:YTEN) is set to provide a comprehensive update on the company’s fourth quarter and full year 2022 financial results on Tuesday, March … Read more

FDA Clears the Way for Wider Access to Breakthrough CycloSam® Treatment for Metastatic Bone Cancer

March 9, 2023 by Allen Williams

QSAM Biosciences Inc. (OTCQB: QSAM) is thrilled to announce that the U.S. Food & Drug Administration has cleared the Company’s amended clinical trial protocol, significantly … Read more

Editas Medicine Bolsters Leadership Team with Appointment of Linea Aspesi as Chief People Officer

March 9, 2023 by Allen Williams

Editas Medicine, Inc. (Nasdaq: EDIT) has announced the appointment of Linea Aspesi as its Executive Vice President and Chief People Officer. Ms. Aspesi will leverage … Read more

Oragenics Bolsters Executive Team by Appointing Janet Huffman as CFO

March 9, 2023 by Allen Williams

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company committed to combating infectious diseases such as COVID-19, is thrilled to welcome Janet Huffman as Chief Financial … Read more

FDA Approves Mesoblast’s Ryoncil to Treat Pediatric GVHD!

March 9, 2023 by Allen Williams

After three years of waiting, Mesoblast has resubmitted its biologic license application for Ryoncil (remestemcel-L), a potential treatment for children suffering from steroid-refractory acute graft … Read more

Unlocking Potential: How Inceptor Bio Empowers Women to Reach Their Leadership Goals

March 9, 2023 by Allen Williams

Women are often the driving force behind innovation, making up nearly half of the life sciences industry in spite of the lingering wage gap. Their … Read more

BioMarin Responds to BridgeBio’s Challenge with an sNDA for Achondroplasia: Game On!

March 9, 2023 by Allen Williams

Biotech giant BridgeBio’s attempt to monopolize the achondroplasia market was dealt a severe blow on Tuesday, when rival Biomarin announced that the FDA had accepted … Read more

Amid Turbulent Market, CODA Closes Up Shop Without Fanfare

March 9, 2023 by Allen Williams

In a time of economic turbulence, one Bay Area biotech, CODA Biotherapeutics, has sadly been forced to close its doors. This is a stark reminder … Read more

Experts Voice Doubts About Roche’s Polivy as First-Line Treatment for LBCL

March 9, 2023 by Allen Williams

The FDA has raised questions about the efficacy and safety of Genentech (Roche)’s Polivy (polatuzumab vedotin-piiq) when used as the first-line treatment for large B-cell … Read more

ASLAN Pharmaceuticals Unveils Groundbreaking DHODH Inhibitor Farudodstat for Alopecia Areata: Join Virtual Research and Development Day to Learn More!

March 8, 2023 by Allen Williams

ASLAN Pharmaceuticals Pte Ltd (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company, is delighted to invite you to join their upcoming virtual research and development day … Read more

Sumitomo Heavy Industries Makes Bold Move to Back Innovative Alpha Fusion Inc. and Their Breakthrough Astatine Radiopharmaceuticals for Targeted Alpha Therapy

March 8, 2023 by Allen Williams

Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) is excited to announce its investment in Alpha Fusion Inc. … Read more

Tessa Therapeutics Revolutionizes Cancer Research with US National Cancer Institute Partnership

March 8, 2023 by Allen Williams

Tessa Therapeutics Ltd., a clinical-stage cell therapy company, has announced an exciting new partnership with the National Cancer Institute (NCI) of the National Institutes of … Read more

Uncovering Reliable Spine Mobility: 3D Surface Topography Scans Reveal Surprising Results in Adolescents

March 8, 2023 by Allen Williams

Spinal surgeons at Hospital for Special Surgery in New York City have discovered a revolutionary way to assess the range of motion of youth with … Read more

Germany Awakes: Mainz Biomed Spreading Awareness of Colorectal Cancer Screening and Early Detection

March 8, 2023 by Allen Williams

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, is launching a series of events to spread awareness of the … Read more

Antev Announces FDA Approved Plan for Revolutionary Drug Teverelix®: Prostate Cancer Treatment for High-Risk Patients Now Closer Than Ever!

March 8, 2023 by Allen Williams

Antev Ltd., a pioneering late clinical-stage biotech company, is thrilled to announce that the US Food & Drug Administration (FDA) has granted written guidance on … Read more

Revolutionizing Cancer Treatment: Bio-Thera Solutions Begins Clinical Trial of Novel Antibody-Drug Conjugate for Advanced Solid Tumors

March 8, 2023 by Allen Williams

Bio-Thera Solutions, Ltd. (SH: 688177) has just announced that the first dose of their cutting-edge antibody-drug conjugate (ADC) has been administered in a Phase 1 … Read more

FDA Advisory Committee to Consider Sage Therapeutics and Biogen’s Zuranolone Treatment

March 8, 2023 by Allen Williams

The U.S. Food and Drug Administration (FDA) recently informed Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) that it does not intend to … Read more

Revolutionary Carteyva® Offers New Hope for High-Risk Large B-Cell Lymphoma Patients in First-Line Treatment Clinical Study

March 8, 2023 by Allen Williams

JW Therapeutics (HKEX: 2126), an independent and pioneering biotechnology company, is making strides in the field of cell immunotherapy with the launch of a clinical … Read more

Exploring a Decade of RNA Delivery: Beyond the Liver

March 8, 2023 by Allen Williams

With the potential to revolutionize the treatment of infectious diseases, cancers and single gene disorders, RNA therapeutics hold immense promise. To make this promise a … Read more

LENZ Therapeutics Raises $83.5 Million to Revolutionize Presbyopia Treatments with LNZ100 and LNZ101

March 7, 2023 by Allen Williams

LENZ Therapeutics, a biopharmaceutical company with two late-clinical stage programs, LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine) that could be potential best-in-class therapies for presbyopia, … Read more

Spectrum Solutions Widens Testing Horizons with Acquisition of Alimetrix and Microarrays Firms.

March 7, 2023 by Allen Williams

Spectrum Solutions® is proud to announce their recent acquisitions of Alimetrix, Inc. and Microarrays, Inc. Alimetrix, Inc. is a molecular diagnostic laboratory that specializes in … Read more

Nutcracker Therapeutics Moves to Strengthen Leadership Team with Appointment of Experienced HR Executive Angela Peters as Chief Human Resources Officer

March 7, 2023 by Allen Williams

Nutcracker Therapeutics, Inc., a biotechnology company committed to developing groundbreaking RNA therapies through its cutting-edge platform, has tapped Angela Peters as its inaugural Chief Human … Read more

European Patients Receive Doses of Revolutionary Lung Cancer Treatment THIO-101 in New Phase 2 Clinical Trial

March 7, 2023 by Allen Williams

MAIA Biotechnology, Inc. (NYSE American: MAIA) is proud to announce that the first two patients have been successfully dosed in Europe in its Phase 2 … Read more

Shorla Oncology Scores Major Breakthrough with FDA Approval of Revolutionary Leukemia Treatment Nelarabine Injection

March 7, 2023 by Allen Williams

Shorla Oncology, a US-Ireland pharmaceutical company, is proud to announce that its oncology drug, Nelarabine Injection, has been approved by the U.S. Food and Drug … Read more

Xenco Medical Achieves Prestigious Recognition as One of Fast Company’s Most Innovative Companies

March 7, 2023 by Allen Williams

Xenco Medical, a pioneering surgical technology company, has been named one of the World’s Most Innovative Companies for 2023 by prestigious Fast Company Magazine. The … Read more

Moderna Races Towards Approval of Breakthrough mRNA Cancer Vaccine

March 7, 2023 by Allen Williams

At Cowen’s 43rd Annual Healthcare Conference in Boston, Stephen Hoge, President of Moderna, revealed that the company is seeking the FDA’s accelerated approval for their … Read more

Merck Gears Up to Launch Groundbreaking Oral PCSK9 Inhibitor for Late-Stage Clinical Trials

March 7, 2023 by Allen Williams

Merck made a major breakthrough in the fight against hypercholesterolemia Monday, as the company announced that its investigational drug, MK-0616, had achieved its primary endpoint … Read more

Malaysia Joins the Fight Against Cancer with US$1.5 Million Investment in AnPac Bio Detection Equipment

March 7, 2023 by Allen Williams

AnPac Bio, a company with operations in the United States and China, has taken a major step in the global cancer detection equipment market with … Read more

FDA to Decide on Breakthrough Gene Therapy for Adults with Severe Hemophilia A: BioMarin Provides Update on ROCTAVIAN™ (Valoctocogene Roxaparvovec)

March 7, 2023 by Allen Williams

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) received exciting news this afternoon: the U.S. Food and Drug Administration (FDA) extended its review of the company’s Biologics License … Read more

Axogen, Inc. Welcomes Marc Began as Executive VP and General Counsel

March 6, 2023 by Allen Williams

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce the appointment of … Read more

Voyager Therapeutics Secures a $25 Million Boost with License of Cutting-Edge AAV Capsids for Neurologic Disease Treatment

March 6, 2023 by Allen Williams

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a pioneering biotechnology company dedicated to pushing the boundaries of gene therapy and neurology, has announced that Novartis Pharma AG … Read more

AnnPac Bio-Medical Science Secures US$5 Million in Funding Through Private Placement

March 6, 2023 by Allen Williams

AnPac Bio, a company with operations in the United States and China focused on early cancer screening and detection, announced that on March 2023, it … Read more

Bellerophon Therapeutics Unveils $5 Million Investment Push with Direct Offering

March 6, 2023 by Allen Williams

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) announced today that it has entered into an agreement with a life sciences-focused institutional investor to sell 718,474 shares of … Read more

Lantern Pharma Launches Starlight Therapeutics to Revolutionize Treatments for CNS and Brain Cancers

March 6, 2023 by Allen Williams

Lantern Pharma, Inc. (NASDAQ: LTRN) has taken a bold step forward in oncology drug development by forming a wholly-owned subsidiary, Starlight Therapeutics Inc., to explore … Read more

Pharmaceutical Regulatory Expert Joins Harrow to Lead Regulatory Affairs and Pharmacovigilance

March 6, 2023 by Allen Williams

Harrow, a prominent U.S. eyecare pharmaceutical company, is pleased to announce the addition of Mark Mannebach, Ph.D., R.Ph. to their team as the new Head … Read more

UroGen Pharma Accelerates Growth with Executive Equity Grants!

March 6, 2023 by Allen Williams

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company devoted to creating and commercializing transformative treatments for urothelial and specialty cancers, has granted inducement restricted stock … Read more

Edgewise Therapeutics Welcomes Accomplished Cardiologist Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

March 6, 2023 by Allen Williams

Edgewise Therapeutics Inc. (NASDAQ: EWTX) is pleased to announce the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox … Read more

Adagene Welcomes Prof. Aurélien Marabelle to Bolster Scientific and Strategic Advisory Board

March 6, 2023 by Allen Williams

Adagene Inc. (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, is proud to welcome Professor Aurélien Marabelle, MD, PhD, to its … Read more

Roche and Acadia Join Forces to Tackle Global Health Issues

March 6, 2023 by Allen Williams

The upcoming week is set to be a quieter one for the FDA, with only two key events scheduled. However, the agency has recently experienced … Read more

PharmAla Biotech and Awakn Life Sciences Partner to Make MDMA Accessible and Reliable

March 3, 2023 by Allen Williams

PharmAla Biotech Holdings Inc. (CSE: MDMA) is thrilled to announce that it has been named the exclusive supplier of MDMA to Awakn LS Europe Holdings … Read more

Can Biopharma Make the Move to a 4-Day Workweek?

March 3, 2023 by Allen Williams

The U.K. recently concluded a groundbreaking six-month pilot program that saw 3,000 employees and 61 employers working a four-day workweek instead of the traditional 40 … Read more

Boston Tech Scene Booms as Novo Grows R&D Operations, Adding Over 200 Jobs!

March 3, 2023 by Allen Williams

Novo Nordisk is investing in the Boston area, with an exciting plan to expand its research and development operations and create over 200 new jobs … Read more

Harnessing the Power of Genetics: George Church-Backed Thymmune Launches to Tackle Overlooked Organ Issues

March 3, 2023 by Allen Williams

George Church, the renowned geneticist, has launched a new venture that is developing cell therapies to regenerate the thymus, enabling the body to restore and … Read more

Revolution Medicines Sets Record-Breaking $300 Million Stock Offering

March 3, 2023 by Allen Williams

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, has just announced the pricing of its underwritten public offering … Read more

Mirion Technologies Raises Funds Through Public Stock Offering by Selling Stockholders!

March 3, 2023 by Allen Williams

Mirion Technologies, Inc. (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the medical, nuclear, defense, and research end markets, … Read more

New Immuno-PET Probe Offers Non-invasive Imaging of Gastrointestinal Tumors, Revealing Promising Results with CLDN18.2 Targeting

March 3, 2023 by Allen Williams

Transcenta Holding Limited (HKEX: 06628), a clinically-advanced biopharmaceutical company with capabilities spanning from discovery to manufacturing of antibody-based therapeutics, is proud to announce the successful … Read more

Matthew Shaulis Takes Charge as Hansa Biopharma’s CCO and US President

March 3, 2023 by Allen Williams

Hansa Biopharma, a leader in enzyme technology for rare immunological conditions, is proud to welcome Matthew Shaulis as Chief Commercial Officer and President of the … Read more

GSK’s RSV Vaccine Triumphs: Adcomm Approval Just One Day After Pfizer’s Defeat!

March 3, 2023 by Allen Williams

The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has given a ringing endorsement to GlaxoSmithKline’s respiratory syncytial virus vaccine … Read more

MorphoSys Drastically Reduces Pre-Clinical Programs, Over One-Sixth of Workforce Dismissed

March 3, 2023 by Allen Williams

MorphoSys AG announced Thursday that it will be taking drastic measures to extend its cash runway, including discontinuing pre-clinical programs and reducing its workforce by … Read more

Expansion Therapeutics Strengthens Scientific Advisory Board with High-Profile Appointments and Updates

March 2, 2023 by Allen Williams

Expansion Therapeutics, Inc., a biotechnology company dedicated to developing life-changing oral medicines for severe RNA-mediated diseases, is proud to announce the addition of three distinguished … Read more

Biotech Breakthrough: Dr. John Ballantyne Invests $3M in CureLab!

March 2, 2023 by Allen Williams

Dr. John Ballantyne, the co-founder of Aldevron, has made a wise investment of $3M in the sister companies CureLab Oncology, Inc. and CureLab Veterinary. Thanks … Read more

Flamingo Therapeutics and Dynacure Join Forces to Create Revolutionary RNA Therapeutics Company to Tackle Cancer

March 2, 2023 by Allen Williams

Flamingo Therapeutics and Dynacure have joined forces to form a powerhouse in oncology. The companies have signed a merger agreement to combine their innovative pipelines … Read more

Herbert Boyer Joins GATC Health’s Board of Advisors: A Giant Leap for Biotech Industry Pioneering Genetecist.

March 2, 2023 by Allen Williams

GATC Health Corp, a technology company revolutionizing drug discovery and disease prediction with AI, is proud to welcome Herbert Boyer – the globally renowned biotechnology … Read more

Aurora Spine Launches Multicenter Study of Revolutionary DEXA-C™ Cervical Interbody System!

March 2, 2023 by Allen Williams

Aurora Spine Corporation, a designer and manufacturer of medical devices that improve spinal surgery outcomes, is proud to announce that its DEXA-C Cervical Interbody System … Read more

Avail Medsystems Unlocks the Door to Increased Access to Quality Care with Premier, Inc. Telehealth Agreement

March 2, 2023 by Allen Williams

Avail Medystems is thrilled to announce that we have been awarded a national group purchasing agreement for telehealth/telemedicine with Premier, Inc., effective January 1, 2023. … Read more

Lilly Gambles Big on Pain Target Novartis Couldn’t Crack: $630 Million

March 2, 2023 by Allen Williams

In a major breakthrough, Confo secured a whopping $40 million upfront in a groundbreaking deal with pharmaceutical giant Eli Lilly. This will enable Confo to … Read more

MorphoSys Halts Pre-Clinical Research Programs: What Does it Mean?

March 2, 2023 by Allen Williams

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that it will be discontinuing its pre-clinical research programs in order to optimize its cost structure. Although the results of … Read more

FDA Approves Promising New Treatment for Glioblastoma Multiforme: Temferon Receives Orphan Drug Designation

March 2, 2023 by Allen Williams

Genenta Science (NASDAQ: GNTA) is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™, their … Read more

Biostage Ushers in New Era with Chairman and CEO Transition

March 2, 2023 by Allen Williams

Biostage, Inc. (OTCQB: BSTG), a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or … Read more

Sarepta Therapeutics Provides Generous Grants to Boost Nasdaq Listing and Advance Innovation

March 1, 2023 by Allen Williams

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has recently taken a major step in its commitment to precision genetic medicine for rare diseases, granting generous equity awards to … Read more

Thomas Videbaek Joins Zymtronix Board of Directors: A New Era of Expertise Begins!

March 1, 2023 by Allen Williams

Today, Zymtronix, Inc., a revolutionary biotechnology company, is proud to announce that Dr. Thomas Videbaek, a highly experienced veteran of the biotech industry and former … Read more

Don Hardison Joins Geneoscopy’s Board of Directors: Bringing Valued Leadership Experience to the Table

March 1, 2023 by Allen Williams

Geneoscopy, a leader in the development of groundbreaking diagnostics for gastrointestinal health, is pleased to welcome Don Hardison to its Board of Directors. With more … Read more

Jaguar Health Receives Orphan Drug Designation for a Second Rare Disease Indication: Microvillus Inclusion Disease (MVID)

March 1, 2023 by Allen Williams

Jaguar Health (NASDAQ:JAGX) is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to crofelemer for the … Read more

Original Shark, Kevin Harrington, Joins FSD Pharma to Unleash His Iconic Entrepreneurial Skills!

March 1, 2023 by Allen Williams

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is proud to announce the addition of Kevin Harrington, an iconic entrepreneur, to its Advisory Board. … Read more

AstraZeneca’s 500-Job Rare Disease R&D Expansion: Unlocking the Potential of New Hub

March 1, 2023 by Allen Williams

In a move that stands in stark contrast to the industry trend, AstraZeneca is investing in its future by expanding its R&D operations in Toronto … Read more

Theravance Takes Drastic Action: Cuts JAK Inhibitor, 17% of Workforce Following Shareholder Criticism.

March 1, 2023 by Allen Williams

Theravance Biopharma has announced that, in order to reduce its headcount by about 17%, it is discontinuing its JAK inhibitor program for lung inflammation. The … Read more

Aptinyx’s Hopes Dashed as Parkinson’s Treatment Fails in Clinical Trials

March 1, 2023 by Allen Williams

Aptinyx’s hopeful drug, NYX-458, has failed to meet its primary endpoint in a Phase II clinical trial involving patients suffering from cognitive impairment associated with … Read more

Revolutionary Treatment for Friedreich’s Ataxia Approved by FDA!

March 1, 2023 by Allen Williams

Just in time for Rare Disease Day, patients with a rare neuromuscular disorder have been given a life-changing gift: the FDA has approved the first-ever … Read more

Groundbreaking Treatment For Friedreich’s Ataxia Receives FDA Approval: MDA Celebrates a Major Step Forward

March 1, 2023 by Allen Williams

On this Rare Disease Day, February 28, the Muscular Dystrophy Association (MDA) celebrates the groundbreaking news from the US Food and Drug Administration (FDA): Omaveloxolone … Read more

Sirona Biochem Reveals Exciting Antiviral Test Outcomes!

February 28, 2023 by Allen Williams

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is thrilled to share the exciting results of its research collaboration with the International Centre for … Read more

BioAtla Shakes Up Executive Leadership With Major Change

February 28, 2023 by Allen Williams

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today … Read more

Aveanna Reports Strong Fourth Quarter and Full Year 2022 Financials – Don’t Miss the Call!

February 28, 2023 by Allen Williams

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) is pleased to announce that the company will release its fourth quarter and full year results on Thursday, March … Read more

Agile Therapeutics Given Extra Time to Reach Nasdaq’s Minimum Share Price

February 28, 2023 by Allen Williams

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, is pleased to announce that Nasdaq has granted them a 180-day extension to regain compliance under … Read more

Uncovering New Insights into Life Sciences: An Upcoming Presentation at the Gordon Conference

February 28, 2023 by Allen Williams

180 Life Sciences Corp. (NASDAQ: ATNF) is thrilled to announce that Professor Jagdeep Nanchahal has been chosen to present at the prestigious Gordon Research Conference … Read more

Microbot Medical Expands Global Reach with Addition of Renowned Physician Francisco C. Carnevale, MD, PhD, FSIR to Scientific Advisory Board

February 28, 2023 by Allen Williams

Microbot Medical Inc. (Nasdaq: MBOT) is proud to announce the expansion of its global reach to South America with the appointment of Francisco C. Carnevale, … Read more

Immuneering to Reveal Q4 & Full Year 2022 Financials & Business Updates – What Will the Future Hold?

February 28, 2023 by Allen Williams

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing innovative medicines to treat a broad range of cancer patients, will be reporting its fourth quarter … Read more

NuVasive Prepares to Make a Splash at March 2023 Investor Events

February 28, 2023 by Allen Williams

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, is transforming spine surgery with its minimally disruptive, procedurally integrated solutions. To discuss the company’s … Read more

The Unexpected Consequences of Compulsory Pay Transparency: Unintended Harm from Forced Compliance

February 28, 2023 by Allen Williams

It’s been two months since California’s Senate Bill 1162, requiring employers to include pay ranges in all job advertisements, took effect – and employers in … Read more

Gearing Up for Potential Breakthroughs: FDA Evaluates Promising Drugs from Cytokinetics, Reata, Regeneron, Pfizer and GSK

February 28, 2023 by Allen Williams

February is set to be a pivotal month for drug approvals, with the FDA poised to deliver three critical decisions. One of these could be … Read more

Fulcrum’s Clinical Hold Challenges the Sickle Cell Space

February 28, 2023 by Allen Williams

Fulcrum Therapeutics’ hopes for its potential sickle cell disease (SCD) treatment, FTX-6058, have been put on hold after the US Food and Drug Administration (FDA) … Read more

uniQure’s Historic Hemophilia B Approval Sets the Stage for Potential Treatments of Huntington’s and ALS

February 28, 2023 by Allen Williams

In an unprecedented year for uniQure, the Massachusetts and Amsterdam-based biotechnology company made history with the U.S. and European approval of the world’s first gene … Read more

Unlocking the Mystery of ALS: Two New Clues Discovered – SYF2 and PIKFYVE!

February 28, 2023 by Allen Williams

Be a part of the puzzle in the ever-evolving therapeutic world with GALLS – a 5,000-piece jigsaw that’s connecting the regulatory edges. As you put … Read more

Shock Waves in Reata Stock After CEO Dunn Steps Down on Eve of Final Ataxia Ruling

February 28, 2023 by Allen Williams

Reata Pharmaceuticals’ dream of becoming the first to secure FDA approval for an effective treatment of Friedreich’s ataxia (FA) has been put on hold after … Read more

Pfizer Courts Seagen in Potential Merger Talks

February 28, 2023 by Allen Williams

Seagen, the Seattle-based biotech firm, is back in the spotlight after reportedly entering into discussions with pharmaceutical giant Pfizer for a possible acquisition. According to … Read more

FDA Neuroscience Chief Billy Dunn Departs, Leaving a Lasting Legacy

February 28, 2023 by Allen Williams

After a tumultuous tenure, FDA neuroscience head Dr. Billy Dunn is leaving his post to pursue other opportunities. An internal FDA e-mail revealed the news, … Read more

Alvotech Set to Showcase 2022 Full Year Financial Results on March 2, 2023

February 28, 2023 by Allen Williams

Alvotech, a global biotech leader in the development and manufacture of life-saving biosimilar medicines, will release its financial results for full year 2022 on Wednesday, … Read more

Rare Disease Day 2023: RemeGen Commits To Raising Awareness and Supporting Rare Disease Patients Worldwide

February 28, 2023 by Allen Williams

As the world celebrates Rare Disease Day 2023, RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331) stands in solidarity with the millions of … Read more

Revolutionizing Lab Automation: Thrive Bioscience Launches CellAssist 4.0 with Enhanced Imaging Features

February 28, 2023 by Allen Williams

Thrive Bioscience Inc. is revolutionizing the field of live cell imaging with their newest Release 4.0 of their CellAssist software. This integrated suite of groundbreaking … Read more

Junshi Biosciences Proves Efficacy of Ongericimab: Phase 3 Clinical Studies Show Promising Results

February 28, 2023February 28, 2023 by Allen Williams

Junshi Biosciences is celebrating a major milestone, having successfully completed two randomized, double-blind, placebo-controlled, multi-center phase III clinical studies (Study nos.: JS002-003 and JS002-006) of … Read more

PharmAla Biotech Launches MDMA Analogs: Opening Doors to New Possibilities!

February 24, 2023 by Allen Williams

PharmAla Biotech (CSE:MDMA) is thrilled to announce the unveiling of a revolutionary Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs). This application, … Read more

Jounce Geared for Major Shakeup as Stock Merger with Redx Reduces Team Size by 57%!

February 24, 2023 by Allen Williams

In a move to further streamline its business, Jounce Therapeutics has unveiled an all-stock merger with the clinical-stage biotech Redx Pharma. This restructuring initiative marks … Read more

AbbVie and Capsida Team Up to Revolutionize Treatment of Eye Diseases with Gene Therapies

February 24, 2023 by Allen Williams

AbbVie, a global biopharmaceutical company, and Capsida Biotherapeutics have just announced a major collaboration that could potentially change the treatment of eye diseases. With a … Read more

Moderna Redoubles R&D Efforts Amid Spikevax Sales Slump

February 24, 2023 by Allen Williams

Moderna ended 2022 with a bang, thanks to the success of their Spikevax sales. As they look forward to 2023, the company is investing heavily … Read more

Novartis Abandons Innovative SCD Gene Therapy Program with Intellia

February 24, 2023 by Allen Williams

Novartis has decided to discontinue its ex vivo sickle cell disease (SCD) program, which was developed using Intellia Therapeutics’ CRISPR gene editing technology. This news … Read more

Graphite Bio Achieves Major Victory Against Sickle Cell Disease, Reduces Workforce by Half

February 24, 2023 by Allen Williams

Graphite Bio has pulled the plug on its much-anticipated gene therapy for sickle cell disease (SCD), nulabeglogene autogedtemcel (nula-cel). The end of the development of … Read more

Celebrating 45 Years of Life-Changing Technological Advances: World Cochlear Implant Day 2023

February 24, 2023 by Allen Williams

Today is World Cochlear Implant Day and MED-EL, a leader in implantable hearing solutions, is celebrating with the millions of people whose lives have been … Read more

Accelerating Breakthroughs for People with Spinal Cord Injuries

February 24, 2023 by Allen Williams

Praxis Spinal Cord Institute is thrilled to welcome three cutting-edge technologies to their SCI Incubate program for 2023 — Battelle, inContAlert, and Focal Lines Technologies … Read more

InnoCare and Keymed Usher in New Era of Treatment with First Subject Dosed in Trial of Revolutionary CCR8 Monoclonal Antibody ICP-B05

February 24, 2023 by Allen Williams

InnoCare Pharma (HKEX: 09969; SSE: 688428) and Keymed Biosciences (HKEX: 02162) made a joint announcement today: the first patient has been dosed with ICP-B05 (CM369), … Read more

New Zealand Pharma Shares 2022 Financials: Conference Call March 2nd at 8am ET

February 24, 2023 by Allen Williams

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) is thrilled to invite you to join its conference call on March 2, 2023 at 2:00 pm CET … Read more

Essential Thrombocythemia Treatment Set for Clinical Trial: PharmaEssentia’s Ropeginterferon Alfa-2b-NJFT to be Tested in North America

February 23, 2023 by Allen Williams

PharmaEssentia USA Corporation, a subsidiary of global biopharmaceutical innovator PharmaEssentia Corporation (TPEx:6446), has recently initiated a Phase 2b clinical trial to assess the efficacy of … Read more

AceLink Unveils Promising New Therapy for Fabry Disease at WORLD Symposium

February 23, 2023 by Allen Williams

AceLink Therapeutics, Inc. has unveiled promising results from their Phase 1 trial of AL01211, a novel therapeutic for genetic diseases. The study demonstrated the medication’s … Read more

AceLink Unveils Revolutionary Preclinical Findings on AL00804 at WORLD Symposium!

February 23, 2023 by Allen Williams

AceLink Therapeutics, Inc., a pioneering biopharmaceutical company dedicated to creating life-changing treatments for genetic diseases, has unveiled the promising early results of AL00804, an oral … Read more

Covalon Sees Strong Start to Fiscal 2023: Improved Q1 Results Reported

February 23, 2023 by Allen Williams

Covalon Technologies Ltd. (the “Company” or “Covalon”), an advanced medical technologies company, is pleased to announce its first quarter fiscal 2023 results, ending December 31, … Read more

Glooko and Sanofi Join Forces to Revolutionize Diabetes Care with SoloSmart® Connectivity for SoloStar® Pen

February 23, 2023 by Allen Williams

Glooko Inc. is thrilled to announce a partnering agreement with Sanofi US to better support people living with diabetes and healthcare professionals. The integration of … Read more

Omega Therapeutics Raises $40 Million in Capital With Stock Offering

February 23, 2023 by Allen Williams

Omega Therapeutics, Inc. (Nasdaq: OMGA) has secured an impressive $40 million in a registered direct offering of 6,920,415 Shares of common stock, with a purchase … Read more

Aprea Therapeutics Launches $5.5 Million Stock Offering to Fund Revolutionary Therapies

February 23, 2023 by Allen Williams

Aprea Therapeutics, Inc. (Nasdaq: APRE) is excited to announce the pricing of its public offering of 1,050,000 shares of common stock at a public offering … Read more

Astellas Unveils Breakthrough Results of Pompe Gene Therapy Trial: A Potential Life-Changing Treatment

February 23, 2023 by Allen Williams

At the 19th Annual WORLDSymposium 2023, Astellas presented promising preliminary safety and efficacy data from their Phase I/II FORTIS trial of AT845 in late-onset Pompe … Read more

Apellis Pharmaceuticals Launches Public Offering of Common Stock and Pre-Funded Warrants – Pricing Announced!

February 23, 2023 by Allen Williams

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) is excited to announce the pricing of its public offering of 3,174,603 shares of common stock and pre-funded warrants to purchase … Read more

Keymed and Lepu Biopharma Strike Global Exclusive Licence Deal with AstraZeneca to Develop CMG901

February 23, 2023 by Allen Williams

Keymed Biosciences Inc. and Lepu Biopharma Co., Ltd. have today made a landmark agreement with AstraZeneca, granting them exclusive global rights to develop, manufacture and … Read more

Unlock Financial Insights: Join Orthofix Medical for Their Fourth Quarter Earnings Release and Conference Call on March 6, 2023

February 22, 2023 by Allen Williams

On Monday, March 6, 2023, Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, will be releasing their fourth quarter 2022 financial results … Read more

Processa Pharmaceuticals Unveils Breakthrough Therapies to Revolutionize Cancer Treatment

February 22, 2023 by Allen Williams

Processa Pharmaceuticals (Heatwurx Acquired Promet), Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) is focused on developing its Next Generation Chemotherapies (NGCs) to improve the safety-efficacy … Read more

New South Wales and Myeloid Therapeutics Join Forces to Create Innovative GMP Manufacturing Facility for Groundbreaking RNA Immunotherapies

February 22, 2023 by Allen Williams

Myeloid Therapeutics Inc., a clinical-stage mRNA-immunotherapy company, is taking a major step towards the commercialization of its RNA therapeutics with the announcement of a collaboration … Read more

Vertex to Unveil New Advances in Health Care at Cowen’s 43rd Annual Conference

February 22, 2023 by Allen Williams

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is pleased to announce that management will be participating in Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, … Read more

Former Board Member Exits Company at Key Moment of Change

February 22, 2023 by Allen Williams

Today, IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) announced that An van Es-Johansson has chosen to step down from her role as a member of … Read more

CareDx Reports on Financial Performance in Fourth Quarter and Full Year 2022

February 22, 2023 by Allen Williams

CareDx, Inc. (Nasdaq: CDNA), The Transplant Company™, is set to report its financial results for the fourth quarter and full year 2022 on Monday, February … Read more

CSL Named Again Among America’s Most Admired Employers by Forbes!

February 22, 2023 by Allen Williams

CSL, a global leader in biotechnology, has once again been recognized as one of America’s Best Employers by Forbes and Statista. This is a testament … Read more

Exploring the Growing Trend of Scientists and Innovators Breaking from Academia to Pursue Industry Careers

February 22, 2023 by Allen Williams

Making the transition from academia to industry can be a daunting prospect, but it is often necessary for researchers to bring their therapeutic visions to … Read more

Akebia’s Anemia Treatment in CKD Patients Facing Further Delay

February 22, 2023 by Allen Williams

The targeted radiotherapy candidate proved a resounding success, with an impressive 75% of patients achieving initial remission after bone marrow transplant (BMT), compared to a … Read more

Akebia’s Anemia-Busting Drug for CKD Patients Faces Further Delay

February 22, 2023 by Allen Williams

Akebia Therapeutics has suffered yet another major setback in the development of vadadustat, a drug designed to treat anemia caused by chronic kidney disease. This … Read more

Pfizer Races Ahead in Infant RSV Prevention, Beating Astra and Sanofi to the Punch

February 22, 2023 by Allen Williams

Pfizer made a major stride forward in the race for an RSV vaccine on Tuesday, as the US Food and Drug Administration (FDA) accepted its … Read more

135M Lifeline for Patients With Neglected Bleeding Disorders: Hemab Comes to the Rescue!

February 22, 2023 by Allen Williams

Hemab Therapeutics has secured a whopping $135 million in its Series B funding round, significantly surpassing its target and paving the way for new treatments … Read more

Ipsen Extends Tender Offer for Albireo Pharma, Inc. to March 2023!

February 22, 2023 by Allen Williams

Ipsen S.A.’s Anemone Acquisition Corp. has extended their tender offer to purchase all of Albireo Pharma, Inc.’s outstanding shares of common stock, at a price … Read more

Relation Therapeutics Unveils State-of-the-Art Integrated Wet–Dry Lab in London’s Knowledge Quarter

February 22, 2023 by Allen Williams

Relation Therapeutics has taken a major step forward in realising their ambition to establish a revolutionary approach to drug discovery with the opening of their … Read more

Revolutionizing Healthcare: Garvan Institute & C4XD Successfully Stratify Patients with Precision Medicine Platform

February 22, 2023 by Allen Williams

C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is thrilled to announce the launch of PatientSeek, a groundbreaking precision medicine platform. This … Read more

Breakthrough Study Finds Promising Results from Novel HIV Vaccine Candidate!

February 22, 2023 by Allen Williams

LinKinVax, a clinical-stage biotechnology company, is thrilled to announce the promising interim results of the ANRS VRI06 Phase I trial evaluating a preventive HIV vaccine. … Read more

NRG Therapeutics Scores $500K from MJFF to Strengthen Parkinson’s Programme

February 22, 2023 by Allen Williams

NRG Therapeutics, Ltd., a pioneering neuroscience company taking on mitochondrial dysfunction, is delighted to announce that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) … Read more

Roivant Sciences Ushers in New Era with Appointment to Board of Directors

February 22, 2023 by Allen Williams

Vivek Ramaswamy, the founder of Roivant Sciences (Nasdaq: ROIV), has taken a bold step and resigned from his board position to focus on his ambitious … Read more

Inducement Grants to Fuel Growth at Avidity Biosciences: Nasdaq Listing Rule 5635(c)(4) Grants Announced

February 22, 2023 by Allen Williams

Avidity Biosciences, Inc. (Nasdaq: RNA) recently granted 27,400 stock options and 13,700 restricted stock units (RSUs) to three new non-executive employees as part of the … Read more

FDA Approves Revolutionary Treatment for Geographic Atrophy: Apellis’ Syfovre

February 22, 2023 by Allen Williams

The FDA has just approved Syfovre (pegcetacoplan), developed by Apellis Pharmaceuticals, as the first ever treatment for geographic atrophy (GA). This rare form of blindness … Read more

Leqembi Approval Just Around the Corner: Eisai Pushes for July Approval!

February 20, 2023 by Allen Williams

Eisai is on the brink of a major breakthrough this summer, with the potential full FDA approval of Leqembi (lecanemab), a new drug for Alzheimer’s, … Read more

Moderna’s mRNA Flu Vaccine: Protection Against A, But Not B

February 20, 2023 by Allen Williams

Thursday brought a flurry of news from Moderna as the company announced the interim results from its Phase III trial of mRNA-1010, a seasonal flu … Read more

Pfizer and Valneva’s Clinical Trial on the Brink of Disaster Due to Possible Regulatory Breaches

February 20, 2023 by Allen Williams

Pfizer and Valneva have dealt a major blow to the development of their Lyme disease vaccine candidate, VLA15, after they uncovered potential violations of good … Read more

Clover Strikes Deal to Bring Quadrivalent Flu Vaccine to China!

February 20, 2023 by Allen Williams

Clover Biopharmaceuticals, Ltd. is proud to announce an exclusive agreement with Adimmune Corporation that enables Clover to distribute AdimFlu-S (QIS) in mainland China, Bangladesh, Brazil … Read more

Astellas Unveils Progress on Fezolinetant: A Potential Breakthrough Drug in the U.S.

February 20, 2023 by Allen Williams

Astellas Pharma Inc. has been granted an extended priority review of its investigational agent ‘Fezolinetant’ by the U.S. Food and Drug Administration. Fezolinetant is being … Read more

ASCO GU: Clinical Data Reveals Reduced Risk of Bladder Cancer Recurrence with BLC Therapy

February 20, 2023 by Allen Williams

At the ASCO Genitourinary Cancers Symposium held in San Francisco, Photocure ASA, The Bladder Cancer Company, presented clinical data from the Veterans Affairs (VA) BRAVO … Read more

Medivir Uncovers Promising Combination of Fostrox and Lenvima to Fight Liver Cancer

February 20, 2023 by Allen Williams

Medivir AB, a pharmaceutical company dedicated to developing innovative treatments for cancer, has successfully completed the initial dose escalation phase of its 1b/2a study on … Read more

WestVac Biopharma: Making Major Strides Towards a Trivalent Recombinant Protein COVID-19 Vaccine that Fights XBB.1.5 and BA.5 Subvariants!

February 20, 2023 by Allen Williams

WestVac Biopharma (Guangzhou) Co., Ltd. has made groundbreaking progress on the development of the world’s first trivalent recombinant protein COVID-19 vaccine against the latest prevalent … Read more

Daewoong Pharmaceutical Achieves Record-Breaking KRW 1.16 Trillion in 2022 Sales, Fexuclue Driving Highest Revenue!

February 20, 2023 by Allen Williams

Daewoong Pharmaceutical (led by CEO Seng-ho Jeon and Chang-jae Lee) announced an impressive 2022 annual report. On a standalone basis, sales soared by 10.1% to … Read more

WHO Grants Pre-Qualification to GC Biopharma’s Revolutionary BARYCELA Treatment

February 20, 2023 by Allen Williams

GC Biopharma, a South Korean biopharmaceutical leader, is thrilled to announce that its varicella vaccine, BARYCELA, has been prequalified by the World Health Organization (WHO). … Read more

Promising Results From INSPIRE Trial: Significant Sorbitol Reduction Achieved in Patients With SORD Deficiency!

February 17, 2023 by Allen Williams

Applied Therapeutics, Inc. (Nasdaq: APLT) is thrilled to announce encouraging sorbitol reduction results from their ongoing global Phase 3 INSPIRE trial. The trial is evaluating … Read more

Unlocking the Potential of Cellular Transplant and Therapy: CareDx Highlights Latest Innovations at 2023 Tandem Meetings

February 17, 2023 by Allen Williams

CareDx, Inc., a pioneering precision medicine company that is transforming the landscape of healthcare solutions for transplant patients and caregivers, is thrilled to showcase its … Read more

Enveda Ushers in Era of Transformation with Three INDs by 2023

February 17, 2023 by Allen Williams

Enveda Biosciences has made a major impact on the medical field since its launch in 2019, raising an impressive $124 million to develop small molecules … Read more

Seagen Silently Soars as it Aims for Blockbuster with Adcetris Amidst Merck Buyout Speculation

February 17, 2023 by Allen Williams

Seagen remained silent on the possibility of a buyout from Merck as they reported their fourth-quarter and full-year financial results Wednesday, leaving investors guessing as … Read more

Grifols Cuts 2,000 U.S. Jobs in Cost-Saving Move

February 17, 2023 by Allen Williams

Grifols, a Spanish drugmaker, made waves on Wednesday with the announcement of a sweeping plan to improve its efficiency and cost-effectiveness. Unfortunately, this move will … Read more

Talaris Lays Off Hundreds, Refocuses Business

February 17, 2023 by Allen Williams

Talaris Therapeutics is undergoing a major restructuring, which includes reducing its workforce by one-third and shifting the focus of its pipeline. This move is poised … Read more

Ex-Alnylam Employees Unite to Unlock Breakthrough Gene Therapy Delivery – Raising $193M

February 17, 2023 by Allen Williams

Aera Therapeutics has burst onto the scene Thursday, joining forces between an Alynlam vet and a CRISPR big wig to tackle one of the most … Read more

U.S. Patent Office Revives Battle: Daiichi Sankyo and Seagen in Patent Dispute

February 17, 2023 by Allen Williams

Today, Daiichi Sankyo Co., Ltd. (TSE: 4568) is pleased to announce that it has been granted its request to re-institute post-grant review (PGR) of the … Read more

Abivax Welcomes Dr. Sheldon Sloan, M.D., as their New Chief Medical Officer

February 17, 2023 by Allen Williams

Abivax SA, a Phase 3 biotechnology company dedicated to developing treatments to modulate the immune system and treat chronic inflammatory diseases, is delighted to welcome … Read more

Pfizer and Valneva Release Progress Report on Groundbreaking Lyme Disease Vaccine Trial!

February 17, 2023 by Allen Williams

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) have made the difficult decision to discontinue the participation of a significant portion … Read more

Revolutionary ASC22 Subcutaneous PD-L1 Antibody Achieves Functional Cure of Chronic Hepatitis B: Presentation at APASL 2023

February 16, 2023 by Allen Williams

Ascletis Pharma Inc. (HKEX:1672) is proud to announce that their subcutaneous PD-L1 antibody, ASC22 (Envafolimab), has been found to potentially provide a functional cure for … Read more

Tubulis Bolsters Leadership Team with Appointment of Experienced ADC Expert Björn Hock as Chief Development Officer

February 16, 2023 by Allen Williams

Tubulis is proud to announce the appointment of Björn Hock, PhD, as its new Chief Development Officer (CDO). With more than two decades of experience … Read more

Filippo Canducci Joins Enthera Pharmaceuticals as Chief Medical Officer

February 16, 2023 by Allen Williams

Enthera Pharmaceuticals, a biotech company pioneering novel biologics for select autoimmune conditions, is pleased to announce the addition of Filippo Canducci MD, PhD to its … Read more

First Patient Dosed in Innovent’s Groundbreaking Phase 3 Psoriasis Clinical Trial: Clearing the Way to a Potential Breakthrough Treatment

February 16, 2023 by Allen Williams

Innovent Biologics, Group (HKEX: 01801), a world-class biopharmaceutical company, has made a major breakthrough in the treatment of plaque psoriasis with the successful dosing of … Read more

Valneva Achieves Record Revenues and Cash Reserves for 2022, Sets 2023 Growth Targets

February 16, 2023 by Allen Williams

Valneva SE, a specialty vaccine company listed on both Nasdaq and Euronext Paris, reported its revenue and cash balance for the full year 2022 and … Read more

EMA Reviewing Leniolisib for Treatment of APDS in Europe: Pharming Offers Update

February 16, 2023 by Allen Williams

Pharming Group N.V. is pleased to announce that the European Medicines Agency’s Committee for Human Medicinal Products has decided to review its Marketing Authorisation Application … Read more

Unlock Your Potential – Join Us for the Year-End Report 2022 Presentation and Webcast!

February 16, 2023 by Allen Williams

IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company pioneering the development of novel treatments for Parkinson’s disease, will be releasing its year-end … Read more

Unprecedented Test Revealed to Monitor CAR-T Therapy’s Impact on Cancer Patients

February 16, 2023 by Allen Williams

Eurofins Viracor LLC, a leader in testing for infectious disease, immunology, and allergy, is proud to announce the launch of a revolutionary test that can … Read more

Unlock the Power of AI to Facilitate Faster Research and Break Through Paywalls!

February 16, 2023 by Allen Williams

As the Biden-Harris administration’s approved measures move closer to fruition, government agencies are now facing the challenge of putting these policies into action. With 2023 … Read more

Grifols Cuts 2,000 Jobs in Push for Efficiency

February 16, 2023 by Allen Williams

Grifols, a Spanish drugmaker, has unveiled a sweeping plan to streamline operations and reduce costs – a decision that will unfortunately result in the loss … Read more

John Reed Sets Sail for J&J to Lead the Charge in R&D

February 15, 2023 by Allen Williams

John Reed is making the leap from Sanofi to Johnson & Johnson, where he is set to become the executive vice president of pharmaceuticals, R&D. … Read more

NeoDynamics Brings On New Board Members – A Fresh Take on Leadership

February 15, 2023 by Allen Williams

NeoDynamics is delighted to announce that Jie Bao and Xiaojun Xu will be transitioning away from their roles on the Board of Directors to focus … Read more

Advanced Melanoma Patients Get Hope with CyPep-1 Monotherapy: First Patient Dosed in New Clinical Study

February 15, 2023 by Allen Williams

Cytovation ASA, a clinical stage immune-oncology company, is excited to report that the first patient has been dosed in its Phase 2a study of CyPep-1, … Read more

Formosa Pharmaceuticals Teams Up with Eyenovia to Create Innovative Solutions

February 15, 2023 by Allen Williams

Formosa Pharmaceuticals (6838.TWO) has entered into an exciting collaboration with Eyenovia, Inc. (NASDAQ: EYEN) to develop innovative ophthalmic products. This groundbreaking agreement brings together Formosa’s … Read more

A Global Chromatography Powerhouse is Born: Astrea Bioseparations and Biotage Join Forces!

February 15, 2023 by Allen Williams

Gamma Biosciences, a KKR-formed life sciences platform, has taken a major step in the advanced therapy market with its agreement with Swedish life sciences company … Read more

Cutera, Inc. Set to Report Record Financial Results for 2022!

February 15, 2023 by Allen Williams

Cutera, Inc. (Nasdaq: CUTR) is set to report its financial results for the fourth quarter and full year of 2022 after the market close on … Read more

Université de Montréal and IRICoR Forge New Exclusive Oncology Partnership with Ipsen, Launching Two Discovery-Stage Programs

February 15, 2023 by Allen Williams

Ipsen, Université de Montréal and IRICoR are excited to announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program … Read more

Bavarian Nordic Announces Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions

February 15, 2023 by Allen Williams

Bavarian Nordic A/S (OMX: BAVA) has just announced a major agreement with Emergent BioSolutions Inc. (NYSE: EBS), acquiring two already-marketed travel vaccines, Vivotif® and Vaxchora®, … Read more

Midatech Pharma PLC Closes Massive $6.0m Private Placement, Switches Brokers

February 15, 2023 by Allen Williams

Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP) is pleased to announce the successful closing of its Private Placement of 10,344,822 Units at an issue price of US$0.58 per … Read more

Mainz Biomed Broadens Reach to Spain and UK, Expanding Its Commercial Footprint Across Europe

February 15, 2023 by Allen Williams

Mainz Biomed is thrilled to announce exciting new partnerships with Marylebone Lab LTD and Instituto de Microecologia, two leading independent laboratories covering England and Spain … Read more

FSD Pharma Takes a Bold Step to Tackle Unmet Medical Needs in Alcohol Misuse

February 14, 2023 by Allen Williams

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is proud to announce the launch of a new research and development program dedicated to tackling … Read more

Valo Therapeutics Revolutionizes Healthcare with EUR 2.23M European Innovation Council Investment in PeptiCHIP Technology

February 14, 2023 by Allen Williams

Valo Therapeutics Oy (ValoTx), the innovator of adaptive immunotherapies for cancer and infectious diseases, is delighted to announce that it has been awarded a grant … Read more

Encision Partners with Vicarious Surgical Inc. to Take Surgical Robotics to the Next Level!

February 14, 2023 by Allen Williams

Encision Inc. (PK:ECIA) is excited to announce that they have signed a Proof of Concept Services Agreement with Vicarious Surgical Inc. The Agreement comes with … Read more

Insulet Set to Make Its Mark at Upcoming 2023 Investor Conferences

February 14, 2023 by Allen Williams

Insulet Corporation (NASDAQ: PODD) – the leader in cutting-edge tubeless insulin pump technology – is pleased to announce that its management team will be presenting … Read more

Breaking News: World’s First mRNA-DegradaBALL Vaccine Ready for Clinical Trial as Lemonex Submits IND for Phase 1

February 14, 2023 by Allen Williams

Lemonex Inc., a biotechnology company at the forefront of mRNA and siRNA therapeutics, recently submitted an Investigational New Drug (IND) application to the Ministry of … Read more

Avanos Medical Reports Record-Breaking Financial Results for 4th Quarter and Full Year of 2022

February 14, 2023 by Allen Williams

Avanos Medical, Inc. (NYSE: AVNS) is set to release its financial results and business highlights for the fourth quarter and full year of 2022 during … Read more

Unlocking the Secrets of T Cell Immunology: BioMed X Launches Revolutionary Discovery Platform

February 14, 2023 by Allen Williams

BioMed X is proud to announce the launch of a revolutionary immunology discovery platform that will revolutionize the way we identify target antigens of human … Read more

Insulet Makes Strategic Move to Secure Groundbreaking Automated Glucose Control Technology

February 14, 2023 by Allen Williams

Insulet Corporation (NASDAQ: PODD), the global pioneer in tubeless insulin pump technology, has made a major acquisition today with the assets of Automated Glucose Control … Read more

NanoString to Unveil Q4 and FY2022 Results, Conference Call Set for Feb 28

February 14, 2023 by Allen Williams

NanoString Technologies, Inc. (NASDAQ:NSTG) is set to report fourth quarter and fiscal year 2022 operating results on Tuesday, February 28, 2023. The leading provider of … Read more

Cullinan Oncology to Introduce Revolutionary New Immune Activator for Cancer Treatment in U.S.

February 14, 2023 by Allen Williams

Cullinan Oncology and Harbour BioMed have teamed up to make a revolutionary breakthrough in cancer treatments, introducing CLN-418/HBM7008- a B7H4 x 4-1BB bispecific immune activator … Read more

Frequency Therapeutics Announces Promising Results for Phase 2b Study of FX-322: A Potential Treatment for Sensorineural Hearing Loss

February 13, 2023 by Allen Williams

Frequency Therapeutics Inc. (Nasdaq: FREQ), a regenerative medicine company pioneering treatments to restore function, unveiled promising clinical results from its Phase 2b study of FX-322, … Read more

MAIA Biotech’s Telomere-Targeting Agent THIO Combination Therapy Significantly Enhances Checkpoint Inhibitor Immune Therapies Atezolizumab and Pembrolizumab for Tumor Inhibition

February 13, 2023 by Allen Williams

MAIA Biotechnology, Inc. (NYSE American: MAIA) is launching its second Phase 2 go-to-market trial to evaluate THIO, the world’s first telomere-targeting agent, as a potential … Read more

Jubilant Therapeutics Secures Approval for Revolutionary GBM Treatment: PRMT5 Inhibitor JBI-778

February 13, 2023 by Allen Williams

Jubilant Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to providing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, … Read more

Breakthrough Clinical Trial: First Patient Receives Dose of Revolutionary Drug ALG.APV-527 from Alligator Bioscience and Aptevo Therapeutics

February 13, 2023 by Allen Williams

Alligator Bioscience AB and Aptevo Therapeutics are delighted to announce that the first patient has been dosed in the companies’ Phase 1 trial of ALG.APV-527, … Read more

New Hope for Parkinson’s Disease Treatment: BioNxt Announces Progress on Rotigotine Patch Commercialization

February 13, 2023 by Allen Williams

BioNxt Solutions Inc. is thrilled to share an update on its commercialization plan for the transdermal Rotigotine patch, a revolutionary treatment for those living with … Read more

IRRAflow System Proves Superior to Passive Drainage – Reduced Catheter Infection Rates Confirmed!

February 13, 2023 by Allen Williams

IRRAS, a commercial-stage medical technology company, recently announced the publication of the first comparative study detailing the use of their novel IRRAflow system. This study, … Read more

Unlocking the Secrets of Neurodegenerative Diseases: Astex and Cardiff University Medicines Discovery Institute Join Forces for Novel Drug Discovery

February 13, 2023 by Allen Williams

Astex Pharmaceuticals (UK) and The Medicines Discovery Institute, Cardiff University have joined forces in a multi-million pound, multi-year collaboration to discover novel small molecule therapeutics … Read more

Aristea, AstraZeneca Spin-Off, Forced to Close After Safety Concerns Halt Flagship Program

February 13, 2023 by Allen Williams

Aristea Therapeutics has made the difficult decision to terminate its Phase II lead program RIST4721 due to safety concerns, resulting in the dissolution of its … Read more

LegoChemBio Secures Rights to Unlock Potential of Antibody From Elthera

February 13, 2023 by Allen Williams

LegoChem Biosciences Inc. (KOSDAQ:141080) has just announced an exciting new license agreement with Elthera AG, a Swiss biotechnology company. This agreement will enable LegoChemBio to … Read more

Revolutionary New Therapy for Regenerative Medicine Receives Fast-Track Approval from FDA

February 13, 2023 by Allen Williams

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company dedicated to discovering, developing, and manufacturing innovative cell therapies and antibody products, is delighted to announce that … Read more

Another Hopeful IL-12 Treatment Option Falls Short as AstraZeneca Refocuses Priorities

February 10, 2023 by Allen Williams

AstraZeneca made a major shift in priorities Thursday, announcing a sweeping cut to its pipeline of drugs in an effort to counterbalance its declining COVID-19 … Read more

Bayer Bows to Investor Demands, Appoints Roche Veteran as New CEO

February 10, 2023 by Allen Williams

Bayer’s supervisory board has responded to investor and shareholder demands by unanimously appointing Bill Anderson, an outsider, as their new CEO. Anderson will step into … Read more

Patient Death Leads to Severe Cuts at Magenta, Leaving Just 16% of Staff

February 10, 2023 by Allen Williams

Magenta Therapeutics has announced a dramatic restructuring that will drastically reduce its workforce, with up to 56 positions being eliminated – a massive 84 percent … Read more

AbbVie Bracing for Biosimilar Tsunami: Humira’s Dominance in Jeopardy

February 10, 2023 by Allen Williams

AbbVie’s much-anticipated Humira cliff has arrived, and the biopharma giant is feeling the impact on its 2023 projections. After releasing Q4 and annual 2022 results … Read more

Nykode Therapeutics and The GOG Foundation Join Forces to Tackle Advanced Cervical Cancer with VB-C-04 Trial

February 10, 2023 by Allen Williams

Nykode Therapeutics ASA, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, is teaming up with the GOG Foundation, Inc. to … Read more

European Investment Bank Grants Evotec € 150 Million Loan – A Major Boost to Business Growth

February 10, 2023 by Allen Williams

Today, Evotec SE – a Frankfurt Stock Exchange-listed MDAX/TecDAX and NASDAQ-traded company – and the European Investment Bank (EIB) are pleased to announce a € … Read more

Claus Steensen Sølje Appointed as WALK’s New CFO – A Financial Milestone for the Company!

February 10, 2023 by Allen Williams

ALK has announced that Claus Steensen Sølje will join their ranks as Executive Vice President and Chief Financial Officer (CFO) from June 1, 2023. He … Read more

BriaCell Therapeutics Corp. Reveals Positive Shareholder Outcome – February 10, 2023

February 10, 2023 by Allen Williams

At the BriaCell Therapeutics Corp. Annual General and Special Meeting of Shareholders for the year ended July 31, 2022, a resounding success was seen with … Read more

Nona Biosciences Breaks Into HCAb-Based Antibody Discovery with Mythic Therapeutics Partnership

February 10, 2023 by Allen Williams

Nona Biosciences, a cutting-edge technology innovator and wholly-owned subsidiary of HBM Holdings Limited, has entered into an exciting collaboration with Mythic Therapeutics, a biotechnology company … Read more

Form 12b-25 Submission Announced By InMed: A Step Closer to Reaching its Goals

February 10, 2023 by Allen Williams

InMed Pharmaceuticals Inc. has taken the initiative to file a Form 12b-25 with the SEC in connection with its Quarterly Report on Form 10-Q for … Read more

Verily Welcomes Utpal Koppikar as New Chief Financial Officer

February 9, 2023 by Allen Williams

Verily, an Alphabet company focused on precision health, is pleased to announce the appointment of Utpal Koppikar as their new Chief Financial Officer. With an … Read more

Vapotherm Raises $23 Million to Fuel Growth

February 9, 2023 by Allen Williams

Vapotherm Inc. (NYSE: VAPO), a global medical technology company committed to the development and commercialization of its proprietary Vapotherm high velocity therapy® products, has recently … Read more

Disc Medicine Set to Make a Splash at SVB Securities Global Biopharma Conference

February 9, 2023 by Allen Williams

John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, Inc. (NASDAQ:IRON), will take part in a virtual fireside chat at the SVB … Read more

Halberd Unveils Successful Strategy for Eliminating Antibiotic-Resistant Bacteria from CDC

February 9, 2023 by Allen Williams

Halberd Corporation (OTC PINK:HALB) has achieved remarkable success with its patent-pending extracorporeal laser eradication process. Through an experimental process conducted by Dr. Chester Cooper and … Read more

Abbott to Bolster Cardiovascular Health with Acquisition of Cardiovascular Systems, Inc.

February 9, 2023 by Allen Williams

Abbott Laboratories (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI) have reached a deal that will see Abbott acquire CSI, a medical device company with a … Read more

Sterling Medical Devices’ Epic Transformation: Merging Entities and Recapitalizing RBC Medical Innovations

February 9, 2023 by Allen Williams

Sterling Medical Devices, a leader in the medical device industry, is proud to announce their merger with RBC Medical Innovations. This strategic move brings additional … Read more

Medexus Achieves Record-Breaking Third Quarter with 35% Revenue Growth Year-Over-Year!

February 9, 2023 by Allen Williams

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has released its financial and operational results for the third quarter of its fiscal year 2023, ending December 31, … Read more

23andMe Soars Ahead: Financials Show Skyrocketing Profits in Q3 FY2023

February 9, 2023 by Allen Williams

23andMe, the leading human genetics and biopharmaceutical company, announced its financial results for the third quarter of its fiscal year 2023, ending December 31, 2022. … Read more

Hammond, LA Gets Eighth Plasma Collection Center, Approved by FDA!

February 9, 2023 by Allen Williams

ADMA Biologics, Inc. (NASDAQ: ADMA) is excited to announce that the company has received U.S. Food and Drug Administration (“FDA”) approval for its eighth ADMA … Read more

Revolutionary Samsung Ultrasound to Revolutionize Women’s Health

February 9, 2023 by Allen Williams

Samsung’s United States headquarters of digital radiography and ultrasound, Boston Imaging, introduces the HERA W10 Elite1; the most advanced model of the HERA platform for … Read more

CHOP Awarded Grant to Help Transform Mitochondrial Research

February 9, 2023 by Allen Williams

CHOP has been awarded an incredible $2.3 million from the Bill & Melinda Gates Foundation to power crucial mitochondria medicine research and unlock the mystery … Read more

Fine-Tuning Performance: Hyperfine, Inc. Welcomes Brett Hale as Chief Administrative Officer & CFO

February 9, 2023 by Allen Williams

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system™, is proud to announce the appointment … Read more

Visage 7: KLAS 2023’s Top-Rated Solution!

February 9, 2023 by Allen Williams

Visage Imaging, Inc., a subsidiary of Pro Medicus Ltd., is thrilled to be the proud recipient of the #1 Universal Viewer (Imaging) ranking in the … Read more

Align Technology Ushers in New Leadership with Appointment of Karim Boussebaa to Head iTero Scanner and Services Business—Yuval Shaked to Step Down at End of 2023

February 9, 2023 by Allen Williams

After nearly six years of successful service at Align Technology, Inc., Yuval Shaked, executive vice president and managing director of iTero scanner and services, is … Read more

Jaguar Health Heads Back to Compliance: Nasdaq’s Bid Price Requirement Met!

February 9, 2023 by Allen Williams

Jaguar Health Inc. (NASDAQ:JAGX) had good news to share on February 7, 2023, as the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) … Read more

Experience the Revolutionary ArthroFree® Wireless Camera System at Upcoming Events Hosted by Lazurite®!

February 9, 2023 by Allen Williams

Lazurite has announced its schedule of upcoming events, where it will be exhibiting, presenting, or attending in support of its revolutionary ArthroFree® wireless camera system … Read more

Unveiling Financial Results: Heska to Report Q4 & Full Year 2022 Earnings on February 28, 2023!

February 9, 2023 by Allen Williams

Heska Corporation (NASDAQ: HSKA), a leading global provider of advanced veterinary diagnostic and specialty solutions, will reveal its fourth quarter and full year 2022 financial … Read more

Revolutionizing Molecular Imaging: Curio Bioscience Launches Groundbreaking High-Resolution Spatial Transcriptomics Solution

February 9, 2023 by Allen Williams

Curio Bioscience has just taken a giant leap forward in the world of gene expression mapping with the launch of Curio Seeker – the world’s … Read more

West Takes Corning Partnership to the Next Level with New Product Launch

February 9, 2023 by Allen Williams

West Pharmaceutical Services, Inc. (NYSE: WST) is proud to announce the expansion of its game-changing collaboration with Corning Incorporated (NYSE: GLW), granting exclusive distribution rights … Read more

EnPlusOne Biosciences Strengthens Expertise with Expanded Scientific Advisory Board

February 9, 2023 by Allen Williams

EnPlusOne Biosciences, Inc., a biotechnology company utilizing the power of enzymes to synthesize RNA oligonucleotides, is proud to welcome Jonathan K. Watts, Ph.D., to its … Read more

Palisade Bio Accelerates Robert McRae to Chief Operating Officer

February 9, 2023 by Allen Williams

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company committed to developing therapies for GI complications, is pleased to announce the promotion of Robert … Read more

PDS Biotech Unveils Groundbreaking Vaccine Technology Providing Powerful Protection Against Viral Infections!

February 9, 2023 by Allen Williams

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company, has taken a major step forward in the fight against infectious diseases, including SARS-CoV-2 and multiple … Read more

Syneos Health Revolutionizes Clinical Trial Research with Equicare’s Cutting-Edge Data Capture and Integration Solutions

February 9, 2023 by Allen Williams

Synos Health®, the leading biopharmaceutical solutions organization, is proud to announce their strategic partnership with Equicare, leveraging proXimity™, a cloud-based software platform that expedites the … Read more

T-knife Therapeutics Welcomes Behzad Kharabi, M.D., as Chief Medical Officer to Lead Clinical Development

February 9, 2023 by Allen Williams

T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company, is proud to announce the appointment of Behzad Kharabi Masouleh, M.D. as Chief Medical Officer. Dr. Masouleh will … Read more

Nimbus Therapeutics Seals Deal with Takeda for Acquisition of Promising TYK2 Subsidiary

February 9, 2023 by Allen Williams

Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines, announced the closing of Takeda’s (TSE: 4502/NYSE:TAK) acquisition of its wholly-owned subsidiary, Nimbus Lakshmi, … Read more

Summit Healthcare and YS Biopharma Set to Unite: Registration Statement Filed and Extraordinary Meeting Date Announced

February 9, 2023 by Allen Williams

Summit Healthcare Acquisition Corp. (Nasdaq: SMIH), and YishengBio Co., Ltd (to be renamed YS Biopharma Co., Ltd.) have received SEC approval for their proposed business … Read more

New Hope for Alzheimer’s Patients: Hoth Therapeutics Reports Breakthrough Results With Its HT-ALZ Treatment!

February 9, 2023 by Allen Williams

Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has released revolutionary proof-of-concept data demonstrating the potential therapeutic cognitive effects of its experimental drug, HT-ALZ, in an … Read more

Ostial Corp Raises $7.5M in Series C Funding to Accelerate Growth

February 9, 2023 by Allen Williams

Ostial Corporation, a revolutionary medical technology company, just announced a major funding milestone: a $7M growth round led by Delos Capital, with AMED Ventures and … Read more

New Funding to Develop Innovative Treatments for Pancreatic Cancer and Anticancer Therapeutics – $2 Million from The Mark Foundation for Cancer Research!

February 9, 2023 by Allen Williams

The Mark Foundation for Cancer Research has unveiled the latest round of recipients of its Drug Discovery Award – an ambitious program designed to fast-track … Read more

A New Opportunity Awaits: aTyr Pharma Launches Public Offering of Common Stock

February 9, 2023 by Allen Williams

aTyr Pharma, Inc. (Nasdaq: LIFE) has begun an exciting new public offering of its common stock, giving investors the opportunity to be part of a … Read more

Garuda Soars to New Heights with $62M Investment in Cutting-Edge Stem Cell Therapies

February 9, 2023 by Allen Williams

Garuda Therapeutics is revolutionizing the medical field with their groundbreaking cell therapy technology. The company recently secured a $62 million Series B round to further … Read more

Roche and Janssen Join Forces to Empower Personalised Healthcare with Innovative Diagnostics

February 9, 2023 by Allen Williams

Roche and Janssen Biotech Inc. are collaborating to bring the next level of precision medicine to patients. By creating companion diagnostics for targeted therapies, Roche … Read more

Celyad Oncology Reveals Promising Results from Clinical Trial of Innovative Cancer Treatment.

February 9, 2023 by Allen Williams

Celyad Oncology, a biotechnology company focused on the development of innovative treatments for CAR T-cell therapies, has announced the publication of the data from the … Read more

AI-Powered Breast Imaging Solution to Revolutionize Care at Dubai Hospital

February 9, 2023 by Allen Williams

Lunit and Agfa HealthCare have achieved a major milestone in breast imaging technologies with the successful implementation of the Breast AI Analysis Package at Dubai … Read more

ATF Medical Strengthens Leadership with Experienced VP of Payer Partnerships & Marketing: Brendan Swift

February 9, 2023 by Allen Williams

Brendan Swift is joining ATF Medical, a national leader in complex rehab technology and accessibility solutions for workers’ compensation, as Vice President of Payer Partnerships … Read more

Vertex Unveils Breakthrough CF Therapy as Generic Demand Soars

February 9, 2023 by Allen Williams

Vertex has provided an update on the late-stage clinical development of its next-in-class triple combination treatment for cystic fibrosis, vanzacaftor/tezacaftor/deutivacaftor, amidst increasing demands for generic … Read more

WHO Pre-Qualifies South Korean Filling and Finish Plant, A Major Milestone for GC Biopharma

February 9, 2023 by Allen Williams

The WHO has bestowed an esteemed honor upon GC Biopharma, the leading biopharmaceutical provider in South Korea. On February 3rd, 2023, the WHO granted prequalification … Read more

Is the Mass Tech Layoff Crisis Spreading to BioPharma? An In-Depth Look

February 9, 2023 by Allen Williams

The tech industry and the life sciences have been forging an ever-closer alliance in recent years. By 2030, the pharma industry is projected to invest … Read more

Experts Discuss Innovative Solutions to Pain Management at BIO CEO Conference

February 9, 2023 by Allen Williams

In the wake of the opioid crisis, finding long-term, non-addictive solutions to manage chronic pain in the U.S. has become an urgent priority for biopharma, … Read more

FDA AdComm to Take Closer Look at GSK’s Hopes for Jemperli to Treat Rectal Cancer

February 9, 2023 by Allen Williams

On February 9th, the FDA’s Oncologic Drugs Advisory Committee (ODAC) will be discussing GSK’s Jemperli (dostarlimab) and its potential to receive accelerated approval for treatment … Read more

First Patient Enrolled in Groundbreaking Clinical Trial of SENS-401 to Combat Cisplatin-Induced Ototoxicity

February 6, 2023 by Allen Williams

Sensorion, a clinical-stage biotechnology company at the forefront of developing novel therapies for the treatment of hearing loss disorders, is pleased to announce that the … Read more

Pliant Achieves Promising Mid-Stage IPF Data, Seeks $175 Raise

February 6, 2023 by Allen Williams

Pliant Therapeutics launched a public offering of its common stock on Monday, with a total of $175 million up for grabs. The proceeds from the … Read more

Babson Diagnostics Revolutionizes Blood Testing with Innovative New Brand Identity

February 3, 2023 by Allen Williams

Babson Diagnostics is revolutionizing the healthcare industry with its cutting-edge technology, BetterWay™ Blood Testing. This innovative diagnostic blood testing service puts the customer first, ensuring … Read more

Cardiff Oncology Launches Revolutionary CAR T Cells to Combat Cancer with Fairooz Kabbinavar, MD, FACP as Chief Medical Officer

February 3, 2023 by Allen Williams

CoImmune, Inc., a clinical stage immuno-oncology company working to revolutionize cancer treatment with cutting-edge cellular immunotherapies, has unveiled exciting preclinical results in Blood, the leading … Read more

Cardiff Oncology Welcomes Dr. Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

February 3, 2023 by Allen Williams

Cardiff Oncology, Inc. (Nasdaq: CRDF), a forward-thinking biotechnology company developing innovative therapies for a range of cancers, is proud to announce the appointment of Fairooz … Read more

Is CRISPR Technology Unfairly Biased?

February 3, 2023 by Allen Williams

Recent studies have exposed a worrying connection between CRISPR gene editing and ancestry: individuals with greater genomic diversity, such as those of African descent, have … Read more

GSK Receives Green Light for New CKD Anemia Treatment – With Caveats

February 3, 2023 by Allen Williams

The US Food and Drug Administration (FDA) has given the green light to GSK’s daprodustat, now branded as Jesduvroq, for treating anemia related to chronic … Read more

Patient Square Reaches Staggering $3.9B Milestone in Inaugural Fundraising

February 3, 2023 by Allen Williams

Patient Square Capital is rewriting the rules of the game when it comes to investing in bear markets and sky-high inflation. On Thursday, they announced … Read more

Karuna Pharmaceuticals Soars High with Acquisition of Goldfinch’s TRPC4/5 Assets for Anxiety and Mood Disorders

February 3, 2023 by Allen Williams

Karuna Therapeutics has made an exciting move, acquiring exclusive rights to Goldfinch Bio’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates in … Read more

Roche Bows Out: AKT Prostate Cancer Treatment No Longer an Option

February 3, 2023 by Allen Williams

Roche has decided to discontinue development of its experimental AKT inhibitor ipatasertib, which had been under investigation in a Phase III trial for castration-resistant prostate … Read more

Structure Therapeutics Launches IPO with Oversubscribed Demand

February 3, 2023 by Allen Williams

Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, is pleased to announce the pricing of its upsized initial public offering of 10,740,000 American depositary shares … Read more

Roivant Sciences Prices Boosted Public Offering of Common Shares!

February 3, 2023 by Allen Williams

Roivant Sciences, Inc. (Nasdaq: ROIV) announced the successful pricing of an upsized public offering of 26,666,666 of its common shares at a price of $7.50 … Read more

New Leadership for Sobi – What Changes Lie Ahead?

February 2, 2023 by Allen Williams

Dr. Anton (Tony) Hoos is set to become the new Head of R&D and Medical Affairs, Chief Medical Officer, and member of the Sobi Executive … Read more

Vera Therapeutics Raises Funds for Revolutionary Therapies with Public Offering of Class A Common Stock

February 2, 2023 by Allen Williams

Vera Therapeutics, Inc. (NasdaqGM: VERA) is delighted to announce the pricing of its underwritten public offering, offering 14,285,715 shares of its Class A common stock … Read more

TAU Systems Makes Major Strides in Plasma Accelerator Development with UT Austin Agreements!

February 2, 2023 by Allen Williams

TAU Systems, a leading provider of ultrafast, compact plasma accelerators, is proud to announce its recent agreements with The University of Texas at Austin (UT … Read more

BerGenBio Bolsters Oncology Research with Scientific Advisory Board Establishment

February 2, 2023 by Allen Williams

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company dedicated to developing innovative AXL kinase inhibitors to address severe unmet medical needs, is proud to announce … Read more

NeoDynamics Joins Forces With Uniphar to Streamline US Distribution and Logistics!

February 2, 2023 by Allen Williams

NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST) is thrilled to announce their new partnership with global distribution and logistics giant Uniphar Group to … Read more

Unlock the Secrets to Success in 2022: A Comprehensive Business Update from Sequana Medical

February 2, 2023 by Allen Williams

Sequana Medical NV (Euronext Brussels: SEQUA), a leader in the field of fluid overload treatment for liver disease, heart failure and cancer patients, will reveal … Read more

Explore the Latest Advances in Otolaryngology at Sensorion’s ARO Posters!

February 2, 2023 by Allen Williams

Sensorion, an innovative clinical-stage biotechnology company, is excited to announce their participation in the Association for Research in Otolaryngology (ARO) 46th Annual MidWinter Meeting in … Read more

Vitrolife AB Reports Strong Profits in Fourth Quarter and Full Year of 2022

February 2, 2023 by Allen Williams

Fourth quarter Sales of SEK 855 (514) million soared by an impressive 66% in SEK, driven by organic growth of 11%, 37% acquired growth, and … Read more

2022: A Year of Progress at Spago Nanomedical!

February 2, 2023 by Allen Williams

OCTOBER – DECEMBER IN BRIEF During the quarter, the company achieved net sales of KSEK 142, a significant increase from the KSEK 99 reported in … Read more

Revolutionary Cancer Treatment: Anaveon’s ANV419 Shows Promise in Pioneering Melanoma Study

February 2, 2023 by Allen Williams

Anaveon, a clinical stage immuno-oncology company, is excited to announce the first patient has been dosed in the OMNIA-1 study – a Phase I/II study … Read more

uniqURE Acquires Life-Changing Gene Therapy to Combat SOD1-ALS

February 1, 2023 by Allen Williams

On Tuesday, uniQure announced an exciting collaboration with Apic Bio to develop and commercialize APB-102, a potential therapeutic treatment for a rare, genetic form of … Read more

Colossal Scores Huge $150M Series B to Take On the Fabled Dodo

February 1, 2023 by Allen Williams

With a colossal $150 million Series B financing round, Colossal Biosciences has taken a giant leap towards the de-extinction of the beloved Dodo – extinct … Read more

STP705: A Potential Breakthrough for Non-Melanoma Skin Cancers? Sirnaomics Pushes for Faster Clinical Development

February 1, 2023 by Allen Williams

Sirnaomics Ltd., a cutting-edge biopharmaceutical company in the discovery and development of RNAi therapeutics, is thrilled to announce that it is making strides in the … Read more

Occlutech Execs Shake Up Management Team

February 1, 2023 by Allen Williams

Occlutech Holding AG, a leader in providing cutting-edge minimally invasive structural heart disease devices, is proud to announce the appointment of Dr. Morwan Choli as … Read more

Bronwyn Brophy Takes the Reins at Vitrolife AB – Get Ready for a New Era!

February 1, 2023 by Allen Williams

Bronwyn Brophy, an Irish national, possesses an impressive resume of leadership positions in some of the world’s most prominent Life Science and Medtech organizations, such … Read more

FDA Approves Ellipses Pharma’s EP0042 for Acute Myeloid Leukaemia Patients!

February 1, 2023 by Allen Williams

Ellipses Pharma, a pioneering drug development company committed to transforming cancer treatment, is delighted to announce that the U.S. Food and Drug Administration (FDA) has … Read more

AviadoBio Welcomes Jeff Goater as New Chair of its Board of Directors!

February 1, 2023 by Allen Williams

AviadoBio, a groundbreaking gene therapy company at the forefront of developing and delivering life-changing treatments for those suffering from neurodegenerative disorders, is proud to announce … Read more

Unlocking the Benefits of Inducement Grants: Adicet Bio Reports Under Nasdaq Listing Rule 5635(c)(4)

February 1, 2023 by Allen Williams

Adicet Bio, Inc. (Nasdaq: ACET) made a major move on January 31, 2023, granting inducement awards to further its mission of discovering and developing allogeneic … Read more

United States Grants Additional Patent to Sequana Medical’s Revolutionary DSR® System

February 1, 2023 by Allen Williams

Sequana Medical NV (Euronext Brussels: SEQUA) proudly announces the granting of a new US patent for its revolutionary DSR (Direct Sodium Removal) program. This groundbreaking … Read more

Amgen Celebrates Record-Breaking Fourth Quarter and Full Year Earnings: Listen to the Webcast Now!

February 1, 2023 by Allen Williams

Amgen (NASDAQ:AMGN) recently held its 2022 fourth quarter and full year financial results webcast, and the full transcript and audio replay are now available for … Read more

Revolutionary Breakthrough: Alpha Biopharma Submits NDA for Zorifertinib to Treat EGFR-mutated NSCLC with CNS Metastases

January 31, 2023 by Allen Williams

Biopharmaceutical innovator Alpha Biopharma proudly announces that the National Medical Products Administration’s Center for Drug Evaluation (CDE) has accepted its New Drug Application (NDA) for … Read more

Industry Veteran Owen Murray Takes the Helm as Aprecia’s CEO

January 31, 2023 by Allen Williams

Aprecia Pharmaceuticals is proud to announce Owen Murray as its new Chief Executive Officer. With Murray at the helm, Aprecia is set to revolutionize the … Read more

Dr. Pavankumar Tandra Joins Florida Cancer Specialists & Research Institute to Offer Cutting-Edge Care in Sarasota

January 31, 2023 by Allen Williams

Dr. Pavankumar Tandra, a board-certified hematologist and medical oncologist, has joined Florida Cancer Specialists & Research Institute, LLC (FCS)! He is now providing exceptional care … Read more

Moderna’s RSV Vaccine Receives Groundbreaking FDA Approval!

January 31, 2023 by Allen Williams

Moderna’s RSV vaccine candidate has been granted a Breakthrough Therapy Designation by the FDA, a major step forward in the fight against the debilitating respiratory … Read more

Novartis’ Hopes for SCD Treatment Dashed by Phase III Trial Results

January 31, 2023 by Allen Williams

Novartis’ hope for a therapeutic breakthrough in the treatment of sickle cell disease, Adakveo (crizanlizumab), is currently under review by the European Medicines Agency’s Committee … Read more

FDA Approves Breakthrough Reversible Drug to Treat B-Cell Cancers!

January 31, 2023 by Allen Williams

Eli Lilly’s revolutionary new drug, Jaypirca (pirtobrutinib), has just been granted accelerated approval by the FDA for treating adults with relapsed or refractory mantle cell … Read more

Unveiling the Challenges of Remote Work and Consolidation for Boston

January 31, 2023 by Allen Williams

Boston is a haven for biotech, boasting an impressive concentration of life sciences companies and the financial resources to back them up. It’s clear that … Read more

Sensorion and EVEON Unveil Revolutionary Injection System for Delivering Gene Therapy Treatments Directly to the Inner Ear

January 31, 2023 by Allen Williams

Sensorion and EVEON have joined forces to design and develop a revolutionary injection system for the delivery of Sensorion’s gene therapy products to the inner … Read more

Amgen Cuts 300 Jobs as Pharmaceutical Industry Struggles

January 31, 2023 by Allen Williams

On Monday, Amgen confirmed to BioSpace that it is making significant organizational changes, including the layoff of around 300 team members, in order to better … Read more

C-mo Medical Solutions Doubles Down, Raises €4.8 Million to Revolutionize Cough Monitoring

January 31, 2023 by Allen Williams

C-mo Medical Solutions is revolutionizing cough assessment and disease management with the power of digital health! With the recent funding from Novalis Biotech, this pioneering … Read more

Kepler Cheuvreux Begins Analyzing MaaT Pharma’s Stock – Here’s What to Expect

January 30, 2023 by Allen Williams

MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech, is revolutionizing the field of cancer treatment with its pioneering Microbiome Ecosystem TherapiesTM (MET). The Company has … Read more

Uncover the Latest Insight: Join Sensient’s Conference Call!

January 30, 2023 by Allen Williams

Sensient Technologies Corporation (NYSE: SXT) is ready to share its fourth quarter and year-end results for 2022 on Friday, February 10, 2023. Join us as … Read more

Angela M. Dowling Set to Make History as First-Ever Kaiser Permanente Leader in Washington

January 30, 2023 by Allen Williams

Kaiser Permanente is proud to announce the appointment of Angela Dowling as their new regional president in Washington. Starting February 13, 2023, she will be … Read more

Dr. Rohit Varma: Pioneering Eye-Disease Research at the 2nd Mexico-United States Symposium on Vision Health

January 30, 2023 by Allen Williams

More than 40 of the world’s most esteemed ophthalmologists, vision researchers, and public health/policy experts are gathering in Mexico for the 2nd Mexico-U.S. Symposium on … Read more

Unlocking Financial Opportunities: How Community Financial Institutions are Helping to Promote Community Development.

January 30, 2023 by Allen Williams

Community Financial Institutions (CFIs) play a vital role in promoting economic and social justice in underserved communities. By providing products and services tailored to the … Read more

Hospital for Special Surgery Announces New Leadership

January 30, 2023 by Allen Williams

Hospital for Special Surgery (HSS) today announced a historic transition for 2023, as Bryan T. Kelly, MD, MBA will become the first surgeon to assume … Read more

XyloCor Takes Giant Leap Forward in Cardiovascular Gene Therapy with Positive Angina Results!

January 30, 2023 by Allen Williams

Just in time for American Heart Month, XyloCor Therapeutics has released positive topline results from their Phase I/II trial of their groundbreaking gene therapy for … Read more

Keytruda Reaches Milestone with Fifth FDA Approval for Non-Small Cell Lung Cancer

January 30, 2023 by Allen Williams

Merck’s revolutionary cancer treatment, Keytruda (pembrolizumab), has been officially approved by the FDA for the treatment of stage IB, II or IIIA non-small cell lung … Read more

Celularity Considers Staff Reductions in New Strategic Review

January 30, 2023 by Allen Williams

Celularity made a startling announcement on Thursday, revealing that it was undertaking a strategic review and warning its employees to brace for possible job losses. … Read more

Antitrust Allegations Spark Market Uncertainty Following Sen. Warren’s Claims

January 30, 2023 by Allen Williams

Sen. Elizabeth Warren (D-MA) is expressing her concerns about the high-priced acquisitions of Horizon Pharmaceuticals and Opiant Pharmaceuticals by Amgen and Indivior, respectively, in a … Read more

Jaguar Health to Forge Ahead with Efforts to Fight Rare and Orphan Diseases in the U.S. and Europe

January 27, 2023 by Allen Williams

Jaguar Health, Inc. is taking a bold step forward in its mission to make a difference in the rare and orphan disease space. Through its … Read more

Biologics Take Giant Leap Forward: Biotech Firm Prepares for NB1 Pilot Clinical Trial with Help from Expert Contract Research Organization

January 27, 2023 by Allen Williams

Bone Biologics Corporation, a leader in developing orthobiologic products for spine fusion markets, is thrilled to announce their collaboration with Avania, a renowned global, full-service … Read more

Study Reveals Successful Transfection of T-cells Using Kytopen’s Flowfect® Technology

January 27, 2023 by Allen Williams

BioCentriq, Inc., a New Jersey-based CDMO for cell and gene therapies, has just concluded a study to evaluate the viability, transfection efficiency, and post-transfection growth … Read more

Nogra Pharma and Torii Pharmaceutical Forge Groundbreaking Deal to Bring Revolutionary Acne Treatment to Japan

January 27, 2023 by Allen Williams

Nogra Pharma, a biotechnology company dedicated to creating groundbreaking therapies for immune-inflammatory-mediated diseases, has just announced a major licensing agreement with Torii Pharmaceutical Co., Ltd. … Read more

Panbela Set to Unleash $15 Million in Public Offerings!

January 27, 2023 by Allen Williams

Panbela Therapeutics Inc., a clinical stage company developing groundbreaking therapeutics for the treatment of patients with urgent unmet medical needs, has announced the pricing of … Read more

Unlock Your Brain Power: 10 In-Demand Neuroscience Jobs You Can’t Afford to Miss!

January 27, 2023 by Allen Williams

The COVID-19 pandemic has sparked an increased demand for biopharma candidates, with the neuroscience field experiencing a particularly noticeable surge. As this sector continues to … Read more

New Study Warns of Increased Risk of Rare VEXAS Syndrome

January 27, 2023 by Allen Williams

A startling revelation was made on Tuesday – a previously unknown syndrome with a high mortality rate is far more common than previously thought. The … Read more

Ocuphire Pushes Ahead with Promising Diabetic Retinopathy Drug Despite Missing Primary Goal

January 27, 2023 by Allen Williams

Ocuphire Pharma is forging ahead with an FDA end-of-Phase II meeting, despite not achieving the primary endpoint with its oral diabetic retinopathy (DR) drug, APX3330. … Read more

AML Trial Halted Following Patient Death

January 27, 2023 by Allen Williams

Magenta Therapeutics has placed an immediate pause on the Phase I/II dose-escalation trial of its AML therapy following the unfortunate death of a patient. The … Read more

Breakthrough Vaccine Candidate Could Revolutionize Treatment of Down Syndrome

January 27, 2023 by Allen Williams

AC Immune’s anti-amyloid-beta vaccine candidate ACI-24.060 has, according to interim data from the Phase Ib/II ABATE trial, been found to be safe and effective in … Read more

Enlivex Unlocks Promising New Treatment Option for Advanced Solid Tumors with Positive DSMB Recommendation

January 26, 2023 by Allen Williams

Enlivex Therapeutics Ltd. has made a significant breakthrough in their pioneering macrophage reprogramming immunotherapy clinical trial, as an independent Data and Safety Monitoring Board has … Read more

Revolutionary Treatments for Early-Stage Dupuytren’s Disease: A Review

January 26, 2023 by Allen Williams

Today, a review providing evidence-based treatments for early stage Dupuytren’s disease has been published in The Journal of Hand Surgery (European Volume) by 180 Life … Read more

Unlocking the Key to Parkinson’s Treatment: Inhibikase Therapeutics Reveals c-Abl as a Promising Target

January 26, 2023 by Allen Williams

Inhibikase Therapeutics, Inc. has made a breakthrough in the battle against Parkinson’s and related disorders. The company recently published a study in Science Translational Medicine … Read more

Phio Pharmaceuticals Reverses Course – Announces January 25, 2023 Stock Split!

January 26, 2023 by Allen Williams

Phio Pharmaceuticals Corp., a clinical stage biotechnology company, is taking a bold step forward with its INTASYL™ RNAi platform technology. On January 26, 2023, the … Read more

Jasper Therapeutics Raises $90 Million in Historic Public Offering of Common Stock

January 26, 2023 by Allen Williams

Jasper Therapeutics, Inc., a biotechnology company that is revolutionizing the field of medicine with its novel antibody therapies, has announced the pricing of an underwritten … Read more

Acasti Reclaims Compliance with NASDAQ: Extends Time to Meet Minimum Bid Price Requirement

January 26, 2023 by Allen Williams

Acasti Pharma Inc., a late-stage specialty pharma company developing treatments for rare and orphan diseases, has been granted a 180-day extension by the NASDAQ Listing … Read more

Psychedelic-Derived Obesity Treatment: Professor Joseph Tam Brings Hope for Future Weight Loss at Isranalytica 2023

January 26, 2023 by Allen Williams

Clearmind Medicine Inc., a pioneering biotech company devoted to uncovering and developing novel psychedelic-derived therapeutics, proudly announced today that Professor Joseph Tam, D.M.D., Ph.D., presented … Read more

Psychedelic Therapy Shows Promising Results in Treating Depression in Clinical Trial

January 26, 2023 by Allen Williams

On Wednesday, Small Pharma made a major breakthrough in the development of treatment for major depressive disorder (MDD) when they reported positive results from their … Read more

Tech Revolution: VC Fund Reaps Massive $350M Windfall as Tech Giants Falter

January 26, 2023 by Allen Williams

On Wednesday, three venture capitalists unveiled an exciting new endeavor: Dimension I, a $350 million fund to revolutionize the biotech industry. With this bold move, … Read more

Merck’s Keytruda: A Tale of Triumph and Disappointment

January 26, 2023 by Allen Williams

Wednesday was an eventful day for Merck’s blockbuster drug Keytruda (pembrolizumab), as it suffered a rare setback in prostate cancer while simultaneously celebrating a major … Read more

T. Denny Sanford Makes Historic Donation to Sanford Burnham Prebys, Aiming to Attract the Best in Biomedical Research

January 25, 2023 by Allen Williams

Sanford Burnham Prebys is proud to announce a major recruitment drive, with up to 20 new faculty positions set to be filled in the fields … Read more

Unlock the Secrets of Biopharma Innovation: Cerevance to Join SVB Global Conference

January 25, 2023 by Allen Williams

Cerevance, a groundbreaking clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, is proud to announce that Craig Thompson, the company’s … Read more

Dyadic Begins Human Testing of its Recombinant Protein RBD Booster Vaccine Candidate to Combat COVID-19

January 25, 2023 by Allen Williams

Dyadic International, Inc., a pioneering biotechnology company, has made a major breakthrough in the fight against COVID-19. The company has initiated dosing in its Phase … Read more

Robert Eno Joins HeartBeam as President, Bringing Decades of Leadership Experience to the Table

January 25, 2023 by Allen Williams

HeartBeam Inc. (NASDAQ: BEAT), a groundbreaking cardiac technology company, is delighted to welcome Robert Eno to their executive team in the newly created position of … Read more

Medical Device Expert Michael Nketiah Joins Nexalin Technology as Senior VP of Quality, Clinical and Regulatory

January 25, 2023 by Allen Williams

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) is thrilled to welcome Michael Nketiah to its leadership team as Senior Vice President of Quality, Clinical and Regulatory. … Read more

New Real-World Study Reveals Risks of Accidental Dosing Errors with Twice-Nightly Oxybates

January 25, 2023 by Allen Williams

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on improving treatments to improve lives, recently unveiled real-world data showing the risk of accidental dosing errors with … Read more

Revealing Study Uncovers Unknown Illness Affecting Thousands

January 25, 2023 by Allen Williams

The discovery of the genetic basis of VEXAS syndrome in 2020 was a major breakthrough in medical research. But how many people in the United … Read more

A New Hope for Long COVID Sufferers: Axcella Clears Regulatory Hurdles

January 25, 2023 by Allen Williams

Axcella Therapeutics is making strides in the fight against Long COVID fatigue with its AXA1125 therapeutic. On Monday, the U.K.’s Medicines and Healthcare products Regulatory … Read more

Biogen-Ionis Adcomm to Put Promising ALS Biomarker to the Test

January 25, 2023 by Allen Williams

On March 22nd, Biogen and Ionis’ experimental therapy for superoxide dismutase 1 (SOD1) ALS, Tofersen, will have its fate in the hands of the FDA’s … Read more

Pliant Reveals Impressive IPF Data, Seeks $175 Increase in Investment

January 25, 2023 by Allen Williams

Monday marked a major milestone for Pliant Therapeutics, as the company launched its public offering of $175 million worth of common stock. These funds will … Read more

Unlock the Potential of Your Specimen – Join Sequire Biotechnology at Their Conference on February 2, 2023!

January 23, 2023 by Allen Williams

Tracy Curley, CEO of iSpecimen Inc. (Nasdaq: ISPC), is excited to be part of the Sequire Biotechnology Conference on Thursday, February 2, 2023. As an … Read more

Hemogenyx Pharmaceuticals PLC: HEMO-CAR-T Successfully Passes Third Process Qualification Run!

January 23, 2023 by Allen Williams

Hemogenyx Pharmaceuticals plc is delighted to announce the successful completion of its third Process Qualification run of the end-to-end manufacturing process for its HEMO-CAR-T cells. … Read more

IntelGenx and Arwan Strike Deal to Bring RIZAPORT® to Middle East and North Africa!

January 23, 2023 by Allen Williams

Today, IntelGenx Corp, a leader in pharmaceutical films, has entered into an exclusive supply agreement with ARWAN Pharmaceuticals Industries Lebanon s.a.l. for their revolutionary product, … Read more

Alvotech Secures $137 Million Investment in Private Share Placement

January 23, 2023 by Allen Williams

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, is pleased to announce the completion of a … Read more

MannKind’s Revolutionary Inhaled Clofazimine Set to Tackle Rare Lung Disease in Adaptive Phase 2/3 Clinical Study

January 23, 2023 by Allen Williams

MannKind Corporation, a leader in the development and commercialization of inhaled therapeutic products to treat endocrine and orphan lung diseases, today announced the launch of … Read more

Revolutionary Machine Vision Technology from Asensus Surgical Now Approved for European Markets!

January 23, 2023 by Allen Williams

Asensus Surgical Inc. has made a thrilling leap forward in medical technology with the CE Mark approval of expanded machine vision capabilities on the previously-cleared … Read more

AstraZeneca Launches Hostile Takeover of CinCor Pharma, Inc. – Can CinCor Fend off the Acquisition?

January 23, 2023 by Allen Williams

Today, AstraZeneca, through a subsidiary, begins a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor) for a combined $36 per share … Read more

European Patent Office Scraps Regenlab’s PRP Patents – Breaking News from Estar Medical

January 23, 2023 by Allen Williams

Estar Medical® has had a string of successes this month in its efforts to invalidate Regenlab’s original patent for platelet rich plasma (PRP) at the … Read more

Revolutionary Cell Therapy Doses First US Leukemia Patient with Smart Immune’s SMART101 Treatment

January 23, 2023 by Allen Williams

Today, Smart Immune SAS, a clinical-stage biotechnology company, made an exciting announcement: the first adult leukemia patient has been successfully dosed with SMART101, a revolutionary … Read more

Helius Medical Technologies, Inc. Sees Record-Breaking Results for Fourth Quarter and Full Year 2022

January 23, 2023 by Allen Williams

Helius Medical Technologies, Inc., a neurotech company with a mission to promote neurological wellness, is pleased to announce preliminary, unaudited results for the quarter and … Read more

Discovering What’s Next: Join TCT BioPharm for a Shareholder Update Call!

January 20, 2023 by Allen Williams

On Monday, February 20th, 2023, TC BioPharm (Holdings) PLC, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, will be … Read more

Experience Explosive Growth with Catent, Inc.: Second Quarter FY 2023 Earnings Conference Webcast

January 20, 2023 by Allen Williams

Catalent, Inc. (NYSE: CTLT) – the global leader in developing, launching and supplying better treatments for patients – will be releasing its financial results for … Read more

Unlock Your Business Potential: Join Us for the Nu.Q® Vet Commercial Strategy Webinar!

January 20, 2023 by Allen Williams

Join VolitionRX Limited (NYSE AMERICAN: VNRX) for an exciting webinar hosted by Edison Group! During the event, Volition’s multi-national epigenetics company will be discussing their … Read more

Jazz Pharmaceuticals Sees $375M Payoff with Zymeworks Investment in GI Cancer Treatment

January 20, 2023 by Allen Williams

Jazz Pharmaceuticals’ $375 million investment into Zymeworks appears to be a smart move, as the two companies announced “impressive” results on Thursday from a Phase … Read more

Uncovering the Secrets of Biotech IP: Ryan Davies Interviews a Leading Expert

January 20, 2023 by Allen Williams

CancerVAX, Inc., a pre-clinical biotechnology company on a mission to develop powerful immunotherapy cancer treatments, is proud to announce that CEO Ryan Davies recently shared … Read more

Dr. Reddy’s Takes Giant Leap Forward With Completion of Clinical Studies for U.S. and European Submission of Rituximab Biosimilar

January 20, 2023 by Allen Williams

Dr. Reddy’s Laboratories Ltd., a world-leading pharmaceutical company, has achieved a major milestone with the successful completion of all clinical trials for its proposed rituximab … Read more

Aptorum Group Executes Dramatic Reverse Stock Split, Ratio of 1-for-10

January 20, 2023 by Allen Williams

At SK bioscience, we are dedicated to promoting global health and wellbeing from prevention to cure. Through our cutting-edge vaccine development technologies, we are standing … Read more

BIOSCIENCE GIANT Appoints New Executives to Drive Ahead with Ambitious Growth Plans

January 20, 2023 by Allen Williams

SK bioscience, a global leader in innovative vaccine and biotech solutions that prioritize human health, has welcomed Richard Kensinger, PhD, to the team as Vice … Read more

Deciphera Pharmaceuticals Launches Public Offering of Common Stock – Invest Now!

January 20, 2023 by Allen Williams

Deciphera Pharmaceuticals, a biopharmaceutical company dedicated to discovering and developing innovative medicines to improve the lives of cancer patients, has announced the pricing of a … Read more

Unlock the Possibility of a Cure for Acute Myeloid Leukemia: BriSTAR Immunotech to Present its Revolutionary Cell Therapy at AACR Special Conference on AML and MDS

January 20, 2023 by Allen Williams

At the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023 in Austin, TX, … Read more

Angle PLC Strengthens Leadership with Appointment of Non-Executive Director

January 19, 2023 by Allen Williams

ANGLE plc, a revolutionary liquid biopsy company, is pleased to welcome Dr. Joseph (Joe) Eid to its board of Non-Executive Directors. Dr. Eid’s appointment will … Read more

Unlocking the Potential of Cell-Specific Promoters: Annogen and VectorY Join Forces in a Groundbreaking Research Collaboration

January 19, 2023 by Allen Williams

Annogen is working to create multiple CNS-cell specific promoters that can be used in VectorY programs. This innovative approach will help to further advance the … Read more

Prenetics Brings Onboard Leading Geneticist Dr. Bayju Thakar as Chief Executive Officer of EMEA

January 19, 2023 by Allen Williams

Prenetics Global Limited, a leader in the fields of genomic and diagnostic testing, is proud to announce the appointment of Dr. Bayju Thakar as CEO … Read more

Scenic Biotech Bolsters Drug Discovery Capabilities with the Appointment of Kristof Van Emelen

January 19, 2023 by Allen Williams

Scenic Biotech, a leader in the groundbreaking world of genetic modifier drugs, has announced the appointment of Kristof Van Emelen, PhD, as Vice President of … Read more

Dr. Peter Hovstadius Joins XNK Therapeutics as Chief Medical Officer

January 19, 2023 by Allen Williams

XNK Therapeutics AB has appointed Dr. Peter Hovstadius as its new Chief Medical Officer, effective immediately. He will join the company’s management team, while Dr. … Read more

NRx Pharmaceuticals Announces Major Progress in Path to NDA Submission for Promising New Treatment: NRX-101

January 19, 2023 by Allen Williams

Last week, NRx Pharmaceuticals, Inc., a clinical-stage central nervous system (CNS) biopharmaceutical company, had a productive meeting with the Food and Drug Administration (FDA), who … Read more

Avail Scientific Signs Letter of Intent to Expand with Acquisition of Florida-Based Relai Neuro Neurological Testing Company

January 19, 2023 by Allen Williams

AVAIL SCIENTIFIC is thrilled to announce that it is taking an exciting step forward by entering into a letter of intent (LOI) to acquire Relai … Read more

Teva’s Bold Climate Goals Confirmed: SBTi Validates Ambitious Targets

January 19, 2023 by Allen Williams

Teva Pharmaceuticals Industries Ltd is proud to have its targets to reduce greenhouse gas (GHG) emissions approved by the Science Based Targets initiative (SBTi), demonstrating … Read more

Repare Therapeutics Reaps Record ¥200 Million Payment from Ono Pharmaceuticals

January 19, 2023 by Allen Williams

Repare Therapeutics Inc., a cutting-edge clinical-stage precision oncology company, announced that it has received a research service payment of approximately $1.5 million (¥200 million) from … Read more

Normunity Strengthens Leadership Team with Appointment of Olga Granaturova as COO and CBO

January 19, 2023 by Allen Williams

Normunity, Inc., a biotechnology company creating innovative precision anti-cancer immunotherapies, is thrilled to announce the appointment of Olga Granaturova, MBA, as Chief Operating Officer and … Read more

Surmodics’ SurVeil™ Drug-Coated Balloon Receives Major Regulatory Boost from the FDA

January 19, 2023 by Allen Williams

SurModics, Inc. announced that they have received a letter from the U.S. Food and Drug Administration (FDA) regarding their premarket approval (PMA) application for the … Read more

bluebird bio, Inc. Launches $120 Million Stock Offering: Time to Invest?

January 19, 2023 by Allen Williams

bluebird bio, Inc. announced the pricing of its public offering of 20,000,000 shares of common stock at a public offering price of $6.00 per share, … Read more

Kaneka Strengthens mRNA Production with Expansion of GMP Manufacturing Capacity at Eurogentec S.A.

January 19, 2023 by Allen Williams

Kaneka Corporation is taking the initiative to expand its GMP manufacturing capacity for mRNA with a capital investment of 2 billion JPY. By the end … Read more

Addex Shines Light on Corporate Progress and Financial Outlook

January 19, 2023 by Allen Williams

Addex Therapeutics Ltd, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a comprehensive corporate update from its headquarters in Geneva, … Read more

Astellas Sets Bold Climate Goals with SBTi Approval of Revised Science-Based Targets to Reduce Greenhouse Gas Emissions

February 6, 2023January 19, 2023 by Allen Williams

KDDI Corporation, based in Tokyo, is proud to announce that its ambitious greenhouse gas (GHG) emissions reduction targets have been validated and approved by the … Read more

Junshi’s Revolutionary PD-1 Blocker Gives Hope to NSCLC Sufferers

January 19, 2023January 19, 2023 by Allen Williams

Junshi Biosciences announced Wednesday that their Phase III Neotorch trial of the anti-PD-1 monoclonal antibody, toripalimab, had achieved its primary endpoint in non-small cell lung … Read more

Novavax’s Nuvaxovid: South Korea Gives the Green Light to COVID-19 Booster Vaccine

January 19, 2023 by Allen Williams

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, is proud to announce that its partner SK bioscience has received … Read more

BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

January 19, 2023 by Allen Williams

BeiGene is making history by expanding access to life-changing drugs in China! For the first time ever, drugs are being added to the nation’s Reimbursement … Read more

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

January 18, 2023 by Allen Williams

BriaCell Therapeutics Corporation is delighted to announce that its lead clinical candidate, Bria-IMT™, in combination with a checkpoint inhibitor, has been met with agreement and … Read more

Lupus Research Alliance Welcomes New Executive VP of Lupus Therapeutics: A Step Forward in the Battle Against Lupus

January 18, 2023 by Allen Williams

The Lupus Research Alliance (LRA) is delighted to announce the appointment of Stacie J. Bell, PhD as Executive Vice President to head up Lupus Therapeutics, … Read more

IceCure Unveils Revolutionary Cryogenic Pump for Next-Gen Cryoablation Systems, Receives Patent Allowance in Japan

January 18, 2023 by Allen Williams

Cryoablation technology is at the forefront of innovation, and we are proud to be a global leader in this field. Our success is evidenced by … Read more

FAP Therapeutic Targeting Achieves Major Success with SOFIE Partnership Grant

January 18, 2023 by Allen Williams

SOFIE Biosciences, a renowned US-based manufacturer of radiopharmaceuticals, is proud to announce its support of Yantai LNC Biotechnology’s recently FDA-approved clinical study – with the … Read more

First Patient Dosed in BOL-148 Clinical Trial: Ceruvia Lifesciences Paves the Way for New Hope in Medicine

January 18, 2023 by Allen Williams

Ceruvia Lifesciences made history today, dosing the first participant in their Phase 1 clinical trial of NYPRG-101 (2-bromo-d-lysergic acid diethylamide). The pioneering trial marks an … Read more

Edesa Biotech Announces Promising Phase 2b Results for Innovative Dermatology Drug

January 17, 2023 by Allen Williams

Researchers have been able to pinpoint the lowest effective dose of a medication or therapy, thanks to a successful study. This breakthrough provides an invaluable … Read more

Perimeter Medical Imaging AI Shakes Up Leadership with Appointment of Suzanne Foster as Board Chair

January 17, 2023 by Allen Williams

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF, FSE: 4PC) – a commercial-stage medical technology company – is proud to announce its new Board … Read more

Unlock Cancer’s Secrets: TCT BioPharm Joins Forces to Harness the Power of Gamma Delta T Cells

January 17, 2023 by Allen Williams

Exploring the role of gamma-delta T cells in oncological settings is an exciting area of research with potentially groundbreaking implications. By devoting our attention to … Read more

Aclarion Welcomes George Frey MD as Latest KOL Surgeon Advisor: Advancing Innovative Solutions for Patients

January 17, 2023 by Allen Williams

Aclarion, Inc., a healthcare technology company utilizing biomarkers and proprietary augmented intelligence algorithms to help physicians determine the source of chronic low back pain, is … Read more

Biobeat Unveils Astounding Ability to Foresee Heart Failure Symptoms During Diuresis

January 17, 2023 by Allen Williams

A recent study published in the Journal of Clinical Medicine has validated the efficacy of Biobeat’s wrist monitor for advanced noninvasive hemodynamic monitoring in heart … Read more

Agilis RoboticsTM Succeeds in Pioneering Endoscopic Surgery with Miniaturized Robotic Instruments on Live Animals

January 17, 2023 by Allen Williams

Agilis RoboticsTM (Agilis) is revolutionizing endoscopic surgery with its groundbreaking robotic instruments. Co-founder Dr. Jason Y.K. Chan recently completed a successful live animal test on … Read more

New Results Show OncoK9 Liquid Biopsy Test Can Revolutionize Cancer Detection in Dogs

January 17, 2023 by Allen Williams

OncoK9’s potential for detecting cancer recurrence and residual disease after surgery or treatment is impressive, as evidenced by the results of PetDx’s analysis. With its … Read more

Ascletis Makes Major Move with Supply Agreement of Ritonavir Tablets and Simcere

January 17, 2023 by Allen Williams

Ascletis Pharma Inc. (HKEX: 1672), a China-based biopharmaceutical company, announced today that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply … Read more

Base Editing Could be a Breakthrough Treatment for Heart Disease

January 17, 2023 by Allen Williams

Scientists from the University of Texas Southwestern Medical Center have made a remarkable breakthrough: using base editing technology, they have managed to repair damaged heart … Read more

CER-001 Shines in Clinical Trial: Promising Treatment for Septic Patients at Risk of Acute Kidney Injury

January 17, 2023 by Allen Williams

We are delighted to report that our clinical trial has produced positive results on both primary and secondary endpoints, allowing us to identify a dose … Read more

China Approves Revolutionary Biosimilar to Actemra®, Providing Hope to Patients Everywhere

January 17, 2023 by Allen Williams

World’s First Approved Biosimilar to Actemra® Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company based in Guangzhou, China, has just made a major breakthrough in medical … Read more

CARsgen Therapeutics and Huadong Medicine Unveil Revolutionary Cancer Treatment: Zevorcabtagene Autoleucel Now Available in China

January 16, 2023 by Allen Williams

CARsgen Therapeutics Holdings Limited (2171.HK) and Huadong Medicine (Hangzhou) Co., Ltd., a subsidiary of Huadong Medicine Co., Ltd. (SZ: 000963), have joined forces in an … Read more

KAZIA Scores Major Funding Boost to Advance R&D Projects

January 16, 2023 by Allen Williams

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is delighted to announce a placement of KZA shares to institutional and sophisticated investors in Australia, at a … Read more

Groundbreaking Scientist in Computational Biology Joins Predictive Oncology’s Scientific Advisory Board

January 16, 2023 by Allen Williams

Predictive Oncology Inc. (NASDAQ: POAI) is thrilled to announce the appointment of Robert F. Murphy, Ph.D. to its Scientific Advisory Board. With his expertise and … Read more

Cytovance Biologics Welcomes Ping Zhang as New Chief Executive Officer

January 16, 2023 by Allen Williams

Cytovance Biologics, a premier biopharmaceutical CDMO of mammalian and microbial biologics, is proud to announce the appointment of Ping Zhang as its new Chief Executive … Read more

Silence Therapeutics Unveils Breakthrough Clinical Programs for SLN360 and SLN124

January 16, 2023 by Allen Williams

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a pioneering biotechnology company dedicated to improving lives by developing precision-engineered medicines to silence diseases, provided … Read more

Unlock the Power of Cell-Based Manufacturing with the New CliniPrime Suite from Charles River

January 16, 2023 by Allen Williams

Introducing CliniPrime Fresh Leukopak, the revolutionary technology that will revolutionize clinical trials and advance the commercialization of advanced therapies. With this launch, we are revolutionizing … Read more

Biolase Named ‘Top Workplace’ for 2022!

January 16, 2023 by Allen Williams

BIOLASE, Inc., the leading global provider of dental lasers, was recently honored with the prestigious Top Workplaces 2022 award from the Orange County Register. The … Read more

Extendicare to Reward Shareholders with C$0.04 Dividend in January 2023!

January 16, 2023 by Allen Williams

Extendicare Inc. (TSX: EXE) declared a cash dividend of C$0.04 per Common Share for the month of January 2023, to be paid out on February … Read more

A Potential Breakthrough: Eisai Submits Marketing Authorization Application for Innovative Treatment of Early Alzheimer’s Disease in Japan!

January 16, 2023 by Allen Williams

BioArctic AB’s partner, Eisai, has recently submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril[1] antibody for the treatment of mild … Read more

Sam Libby Joins EDP Biotech to Fuel Rapid Expansion Plans

January 16, 2023 by Allen Williams

EDP Biotech Corporation is thrilled to welcome Sam Libby as their new Head of Mergers & Acquisitions and Corporate Development. With Libby’s expertise on board, … Read more

IDEXX Partners with Volition to Offer Revolutionary Nu.Q® Vet Cancer Test to Veterinary Patients Everywhere

January 16, 2023January 16, 2023 by Allen Williams

VolitionRx Limited (NYSE AMERICAN: VNRX) is proud to announce the launch of its revolutionary Nu.Q® Vet Cancer Test, now available in the United States through … Read more

ALiA BioTech’s Revolutionary Diagnostic Platform Revolutionizes Multiplex Testing for Medical Professionals

January 16, 2023 by Allen Williams

ALiA BioTech’s rapid diagnostic platform is capable of providing up to 30 accurate results from a single drop of body fluid – whether it be … Read more

Revolutionary Treatment for Early Alzheimer’s Disease in Japan: Eisai Submits Application for Lecanemab Marketing Authorization

January 16, 2023 by Allen Williams

Eisai Co., Ltd. and Biogen Inc. have made a groundbreaking announcement today: they have jointly submitted a marketing authorization application for lecanemab, a revolutionary anti-amyloid … Read more

Clover Aims to Make 2023 a Breakthrough Year with COVID-19 Vaccine Commercial Launch and Strategic Priorities

January 16, 2023 by Allen Williams

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197) has made a commitment to use innovative vaccines to save lives and improve public health across the world. Today, … Read more

First Step to Combatting COVID-19: 4 Healthy Subjects Begin Multiple-Dose Clinical Trial of Oral 3CLpro Inhibitor ASC11

January 16, 2023 by Allen Williams

Enrolling 72 healthy volunteers, we are excited to launch a multiple-dose escalation Phase I clinical trial in the first quarter of 2023. Be a part … Read more

Lilly Unveils ‘Extraordinary Year’ Ahead, Highlighting Promising Pipeline

January 12, 2023 by Allen Williams

Eli Lilly had an incredible year with the launch of their diabetes drug Mounjaro (tirzepatide). Now, the company is gearing up for an even bigger … Read more

Alto’s Groundbreaking Biomarker Test Shows Promising Results in Treating Depression

January 12, 2023 by Allen Williams

As JP Morgan week kicked off in 2023, Alto Neuroscience was named number seven on BioSpace’s NextGen Bio 2023 list and brought with it positive … Read more

AbbVie Braves Uncertainty with Humira, Asserts Unwavering Commitment to Long-Term Growth

January 12, 2023 by Allen Williams

At the 41st J.P. Morgan Healthcare Conference in San Francisco, AbbVie’s CEO Rick Gonzalez talked about the company’s plans to adjust to the impending loss … Read more

Midatech Pharma PLC Advances MTX-110 Phase 1 Study with Planned Dose Escalation

January 12, 2023 by Allen Williams

Midatech Pharma PLC is delighted to announce that their Phase I study of MTX-110 in recurrent glioblastoma (NCT 05324501) will continue with a planned dose … Read more

IRLAB Unveils Exciting New Drug Candidate IRL1117 from P003 Project to Combat Parkinson’s Disease!

January 12, 2023 by Allen Williams

IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a Gothenburg-based company developing pioneering treatments for Parkinson’s disease, has nominated a drug candidate from its P003 research … Read more

Revolutionary PRIMA Implant Restores Vision at 5X Higher Resolution: Groundbreaking Study Reveals Potential

January 12, 2023 by Allen Williams

Pixium Vision has achieved a major milestone — the publication of two peer-reviewed studies showcasing the potential of the Next Generation PRIMA implant to restore … Read more

Biophytis Braces for Action After Receiving Nasdaq Deficiency Notice

January 12, 2023 by Allen Williams

Biophytis SA (NasdaqCM: BPTS)(Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics to slow the degenerative processes of aging and … Read more

Breakthrough Trial Results: Oramed’s ORMD-0801 Proven to Significantly Improve Type 2 Diabetes Treatment!

January 12, 2023 by Allen Williams

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company dedicated to the development of oral drug delivery systems, has released the top-line results of its … Read more

iNtRON Completes Tech Transfer for Revolutionary SAL200 Technology

January 12, 2023 by Allen Williams

iNtRON Biotechnology is delighted to announce that their Tech Transfer process for SAL200, a revolutionary endolysin-based biologic, is entering its final stage! This out-licensing and … Read more

Mountain Valley MD Announces Chief Medical Officer Moving to Advisory Role: New Era Ahead

January 12, 2023 by Allen Williams

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a biotech business focused on the licensing and reselling of … Read more

FDA Clears MTD Group’s Groundbreaking Passive Safety Needle: Innovative Design for Safer Injections

January 11, 2023 by Allen Williams

MTD Group – a global leader in medical devices – is proud to announce that its affiliate Pikdare S.p.A. has just obtained FDA clearance for … Read more

S2 Genomics Partners with Bonsailab to Deliver Cutting-Edge Life Science Solutions to Iberian Peninsula

January 11, 2023 by Allen Williams

S2 Genomics, Inc., a leader in single-cell genomics and cell biology applications, is thrilled to announce its new distribution agreement with Bonsailab. This agreement enables … Read more

Axonics Sees Early 2022 Revenue Surge and Predicts Further Growth in 2023

January 11, 2023 by Allen Williams

Our total company net revenue is expected to skyrocket over the next two years! For Q4 of 2021, we forecast an impressive 61% y/y increase, … Read more

Unveiling the Future of Animal Health Care: Zomedica to Present at Sidoti Virtual Investor Conference

January 11, 2023 by Allen Williams

Zomedica Corp. (NYSE American:ZOM), a veterinary health company that provides point-of-care diagnostics and therapeutic products for companion animals, announced that CEO Larry Heaton will be … Read more

U.S. Trade Judge Finds Apple Guilty of Stealing Masimo’s Pulse Oximeter Technology

January 11, 2023 by Allen Williams

Apple has been found to be in violation of the Tariff Act of 1930, after a United States Administrative Law Judge in Washington, D.C. determined … Read more

Mirum Pharmaceuticals Grants Inducements to Achieve Nasdaq Listing Rule 5635(c)(4) Compliance – Jan 11, 2023

January 11, 2023 by Allen Williams

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) granted inducement awards to four new employees under its 2020 Inducement Plan on January 10, 2023. Each employee was offered … Read more

MediciNova Set to Secure Canadian Patent for Scleroderma and Systemic Sclerosis Treatments MN-001 and MN-002!

January 11, 2023 by Allen Williams

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), has … Read more

Eisai Submits Groundbreaking Application to EU for Lecanemab as Treatment for Early-Stage Alzheimer’s Disease

January 11, 2023 by Allen Williams

BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has made a major move in the fight against Alzheimer’s disease today, submitting a marketing authorization … Read more

10 February 2023: Don’t Miss Out on an Extraordinary Opportunity — Join Us for the Shareholders’ EGM at Sequana Medical!

January 11, 2023 by Allen Williams

Sequana Medical NV (Euronext Brussels: SEQUA), a leader in the treatment of fluid overload in liver disease, heart failure, and cancer, is cordially inviting all … Read more

Basilea Surpasses 2022 Revenue Guidance, Announces Portfolio Updates!

January 11, 2023 by Allen Williams

Fiscal year 2022 was a banner year for Basilea Pharmaceutica Ltd, with significant revenue contributions from the commercial success of Cresemba and Zevtera and proceeds … Read more

Santhera Makes Major Move: Closes CHF 5 Million Share Exchange Deal

January 10, 2023 by Allen Williams

Santhera Pharmaceuticals (SIX: SANN) is pleased to announce that, through a share exchange, it will receive the equivalent of CHF 5 million Idorsia shares. This … Read more

Revolutionary Ameluz-PDT Study Begins: First Patient Dosed in Phase 3 Clinical Trial for Actinic Keratosis Treatment!

January 10, 2023 by Allen Williams

Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced a major milestone in its development as the first patient … Read more

Unveiling the Promising Results of IGM-8444: IGM Biosciences Announces Updates on Phase 1 Trial and Future Clinical Development

January 10, 2023 by Allen Williams

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company dedicated to the development of IgM antibodies, today shared an update on its clinical development program … Read more

Novocure Reports Record-Breaking 2022 Revenues and Offers Company Update

January 10, 2023 by Allen Williams

NovoCure Ltd. (NASDAQ: NVCR), a global oncology company dedicated to extending survival for those suffering from some of the most aggressive forms of cancer, announced … Read more

76 Revio Systems Ordered in Fourth Quarter: Pacific Bio Sees Record Growth in 2022

January 10, 2023 by Allen Williams

PacBio is thrilled to announce the launch of their PacBio Compatible Program, accompanied by positive Onso Beta feedback and preliminary fourth quarter 2022 revenue figures. … Read more

PerkinElmer Set to Unveil Fourth Quarter Results on Tuesday: Get Ready for Big News!

January 10, 2023 by Allen Williams

PerkinElmer Inc., a leading innovator driving a healthier world, will announce its fourth quarter and full year 2022 financial results on Tuesday, February 14th, 2023 … Read more

Celltrion and Rani Therapeutics Unveil Revolutionary Oral Monoclonal Antibody Treatment

January 10, 2023 by Allen Williams

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) – a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs – today announced an exciting … Read more

Unlocking Global Opportunities: SK Bio Night in San Francisco

January 10, 2023 by Allen Williams

SK Inc. is set to spark innovative ideas and identify new business opportunities with its global strategy and growth roadmap at an event attended by … Read more

Berkeley Lights Unveils Revolutionary Optofluidic System, Beacon Select™, to Streamline Cell Line Development

January 10, 2023 by Allen Williams

Introducing a revolutionary new optofluidic system – a two-chip, single-cell device perfect for small to mid-sized biopharma and CDMOs/CROs. Now, you can have access to … Read more

Older posts
Page1 Page2 Next →
©2023